Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation

Prithi Raguraman ¹,²,†, Akilandeswari Ashwini Balachandran ¹,²,†, Suxiang Chen ¹,², Sarah D. Diermeier ³ and Rakesh N. Veedu ¹,²,*

Simple Summary: Splicing is an important mechanism by which precursor mRNA is modified into mature mRNA. This splicing plays a major role in the generation of different proteins required for cells. Cancer cells modulate this splicing in such a way that it facilitates uncontrolled growth and survival. Cancer is one of the leading causes of death, and the therapies that are currently available also affect normal cells. Antisense oligonucleotides (AOs) are synthetic DNA/RNA that bind specifically to target mRNA and thereby have fewer off-target effects. These AOs have the potential to modulate the splicing mechanism. In this review, we will discuss the different modes of action of AOs and their potential in targeting cancer.

Abstract: Splicing is an essential process wherein precursor messenger RNA (pre-mRNA) is reshaped into mature mRNA. In alternative splicing, exons of any pre-mRNA get rearranged to form mRNA variants and subsequently protein isoforms, which are distinct both by structure and function. On the other hand, aberrant splicing is the cause of many disorders, including cancer. In the past few decades, developments in the understanding of the underlying biological basis for cancer progression and therapeutic resistance have identified many oncogenes as well as carcinogenic splice variants of essential genes. These transcripts are involved in various cellular processes, such as apoptosis, cell signaling and proliferation. Strategies to inhibit these carcinogenic isoforms at the mRNA level are promising. Antisense oligonucleotides (AOs) have been developed to inhibit the production of alternatively spliced carcinogenic isoforms through splice modulation or mRNA degradation. AOs can also be used to induce splice switching, where the expression of an oncogenic protein can be inhibited by the induction of a premature stop codon. In general, AOs are modified chemically to increase their stability and binding affinity. One of the major concerns with AOs is efficient delivery. Strategies for the delivery of AOs are constantly being evolved to facilitate the entry of AOs into cells. In this review, the different chemical modifications employed and delivery strategies applied are discussed. In addition to that various AOs in clinical trials and their efficacy are discussed herein with a focus on six distinct studies that use AO-mediated exon skipping as a therapeutic strategy to combat cancer.

Keywords: antisense oligonucleotide; splice switching; cancer therapy

1. Introduction

RNA splicing is a form of RNA processing in which a freshly made precursor messenger RNA (pre-mRNA, or primary transcript) is transformed into a mature mRNA. The process of splicing is catalyzed by the RNA-protein complex known as the spliceosome.
The spliceosome consists of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5 and U6 [1]. During splicing, introns are removed, and exons are joined together.

Splicing can create a range of transcript variants by varying the exon composition of the same transcript. This phenomenon is termed alternative splicing. Alternative splicing is an indispensable process for expanding the spatiotemporal complexity of the transcriptome [2]. More specifically, it is the process wherein the exons of any primary transcript get rearranged to form an mRNA splice variant, and subsequently, the protein isoform, which are distinct both structurally and functionally [3]. In humans, more than 70% of multiexon genes undergo alternative splicing [4]. These splicing events are very tightly regulated and are highly tissue-specific [5]. Different cis- and trans-acting factors regulate the splicing process as they determine the splice site selection [6]. These splice sites can be weakened or strengthened due to point mutations, ultimately changing the splicing events, resulting in disease [6]. Furthermore, in most eukaryotic organisms, there are certain sequences that are ignored by the splicing machinery. These are known as the pseudoexons. In recent years, it has been reported that atypical inclusion of pseudoexons is more frequent than previously understood and is implicated in many human diseases, such as Duchenne muscular dystrophy (DMD) [7].

Cancer is caused by abnormal cell proliferation resulting from altered gene expression [8]. This can include overexpression of oncogenes [9] and production of aberrant splice variants, which subsequently leads to synthesis of carcinogenic protein isoforms [10]. In the past few decades, new developments into understanding the biological basis for cancer progression and therapeutic resistance have led to the identification of many alternative splicing events, which are key in the development of cancer. These carcinogenic splice isoforms are involved in various cellular processes, such as apoptosis, cell signaling and proliferation [11].

Strategies to inhibit the expression of oncogenes and the carcinogenic splice variants of essential genes at the mRNA level have become popular in the past few decades. PremRNA or mRNA with known nucleotide sequences offer a chance to design antisense oligonucleotides (AOs) specific to the transcripts. AOs are short 15–30-base long DNA or RNA molecules that are chemically modified [12]. AOs are designed to be complementary to the target sequence. AOs bind to the target RNA through Watson–Crick base pairing. The specificity of AOs depends on the accuracy of the Watson–Crick base pairing on the estimate that a particular sequence of >16 bases occurs only once in the human genome [13]. Typically, AOs are chemically modified to improve target binding affinity and stability [14,15]. Efficient delivery of AOs into target cells is challenging. Strategies for the delivery of AOs are continually improved to ease the entry of the AOs into the cells [16].

Mechanisms of action of AOs are elucidated in the next section. AOs that induce RNase H-mediated mRNA degradation have been widely used for downregulation of oncogenes [11,17,18]; therefore, this review focuses primarily on six distinct studies that use AO-mediated splice modulation as a therapeutic strategy, with a discussion of different chemical modifications used and delivery strategies employed. In addition, although premature termination of a codon induced by AO-mediated exon skipping has not yet been reported for the development of anticancer AOs, this can potentially be a useful strategy of AO-based cancer therapy (Figure 1).
Figure 1. Schematic illustration of the AO-induced anticancer effect. (Upper): normal cell and tissue. (Middle): activation of oncogene leads to production of oncogenic proteins, and the aberrant splicing of normal gene results in splice variants that are translated into carcinogenic protein isoforms; these carcinogenic proteins collectively promote cancer cell proliferation. (Lower): AO-mediated splice switching can not only correct the aberrant splicing, thus reducing the production of carcinogenic protein isoforms (this is the focus of the present review), but can also induce premature stop codons in oncogenic mRNA that results in the synthesis of largely truncated, nonfunctional oncogenic proteins (this is a potential anticancer strategy). Collectively, AO intervention can inhibit cancer cell proliferation.

2. Mechanism of Action of AOs

A multitude of proteins are responsible for the normal functioning of cells. However, proteins are coded by a smaller number of genes. Briefly, alternative splicing is a process where the same gene can code for multiple proteins via exon inclusion, exon skipping or trimming of specific exons (Figure 2A) [17]. Aberrant splicing can be a cause of many disorders, including cancer. Correction of aberrant splicing using AOs is a widely studied approach. AOs are chemically modified short oligonucleotide that targets a specific mRNA or pre-mRNA by hybridization through Watson–Crick base pairing. These oligonucleotides inhibit the function of the RNA. Typically, there are three different mechanisms that are employed in the modulation of RNA function. They are (i) RNase-H mediated cleavage of the mRNA-DNA duplex (Figure 2B), (ii) steric block-mediated translation arrest (Figure 2C,E,F), and (iii) modulation of the pre-mRNA splicing to regulate expression of the target gene (Figure 2D) [12,17].
Cancers 2021, 13, x 4 of 28

Figure 2. Mechanism of action of AOs to alter gene expression. (A) Normal gene expression process; (B) AO-induced RNase H-mediated mRNA degradation; (C) AO-induced translational repression; (D) AO-induced splice modulation; (E) AO-induced inhibition of polyadenylation; (F) AO-induced inhibition of 5′ capping.

RNase H-mediated cleavage is activated when an AO binds to a complementary target mRNA, forming a DNA-mRNA heteroduplex. The duplex recruits the ubiquitously expressed RNase-H endonuclease enzyme that selectively cleaves the duplex by hydrolyzing the inter-nucleotide phosphate linkage and thereby inhibiting target gene expression [19]. This approach is particularly effective when the AOs are made of oligodeoxyribonucleotides. On the other hand, a steric block involves the AOs physically blocking the binding motifs of interacting proteins, such as at the 5′-cap site, ribosome binding site or translation start site [20].

AOs can also be designed to target pre-mRNA to modulate RNA processing. Splice-switching AOs can manipulate processes such as exon skipping, exon inclusion and intron retention (Figure 3) by targeting the pre-mRNA splicing factor binding sites. AOs binding to the target mRNA can effectively alter the reading frame of the transcripts by inducing exon skipping, allowing the production of a partially functional protein [21]. This attribute of AOs has been well studied in the treatment of DMD [22]. In DMD, mutations in the exon leading to a premature stop codon is rectified by removing the mutated exon. Exondys 51 (eteplirsen) and Vyondys 53 (golodirsen) are two such FDA-approved drugs that target exon 51 and 53, respectively [23–25]. It is also observed that AO-mediated exon skipping can disrupt the reading frame and knock down the protein [26]. In theory, AOs can also be used to target exonic or intronic silencers and can restore an exon in a disease-associated exon skipping framework.
Figure 3. Representation of AO-mediated splice modulation, including (A) exon skipping, (B) exon inclusion, and (C) intron retention. Specially, exon skipping can be used to (A1) remove nonsense mutation to restore essential protein expression, or (A2) induce a premature stop codon or (A3) remove an exon-encoding active site to downregulate the expression of an unwanted protein. Exon inclusion can be used to increase the production of an essential protein, while intron retention may be used to reduce the expression of an unwanted protein by inducing translational repression. In addition, AOs can also target other sites in the mRNA, including cleavage stimulation factor (CstF), polyadenylation specificity factor (CPSF) or polyadenylation signal sequences, and can stop the process from promoting translation arrest [12,27]. Splice-modulating AOs can also be utilized to cause exon inclusion and intron retention in addition to exon skipping. The exon-inclusion strategy has worked well both in vitro and in vivo as a therapeutic approach for spinal muscular atrophy (SMA) [28]. Nusinersin (Spinraza), an approved drug for SMA, works by modulating the splicing of the SMN2 gene, which facilitates the integration of exon 7 into the mRNA, thus enhancing full-length SMN protein production in the central nervous system [29]. Figure 3 summarizes the techniques employed by AOs with particular emphasis on exon-skipping AOs. Although AOs are diligent in inducing exon skipping for a robust therapeutic effect, it is essential
that they reach the target region in the desired amount. To enhance the potential of AOs, various chemical modification and delivery mechanisms are employed.

3. Chemical Modifications

Antisense oligonucleotides made of natural nucleotide monomers are not suitable for therapeutic applications. Stability against nucleases, target-specific binding, tissue distribution and cellular uptake are some of the major concerns with AOs composed of natural nucleotide monomers [30]. Chemically modifying the AOs addresses some of these limitations. Chemical modifications can be introduced at the backbone, nucleobase and sugar moiety. Some of the most commonly used chemical modifications are discussed in this section.

Changes made to the phosphodiester backbone usually replace the non-bridging oxygen atom with carbon (methyl phosphonate, phosphotriester), sulphur (phosphorothioate), nitrogen (phosphoroamidate) or boron (boranophosphate) [31]. Modifying the backbone provides AO stability against nuclease degradation [11]. Examples of sugar modifications include 2′-O-methyl (2′-OMe), 2′-O-methoxyethyl (2′-MOE), locked nucleic acid (LNA), 2′-fluoro RNA (2′-F), hexitol nucleic acid (HNA), cyclohexenyl nucleic acid (CeNA), altritol nucleic acid (ANA), 2′-O, 4′-C-ethylene-bridged nucleic acid (ENA), and morpholino nucleic acid (MNA) (Figure 4). Alterations to the sugar moiety generally increase the binding affinity of AOs, protects AOs from nuclease degradation and increases its specificity [17].

Figure 4. This figure depicts some of the most common or novel chemically modified nucleotide analogues used in constructing splice modulating AOs. 2′-OMe: 2′-O-methyl; 2′-MOE: 2′-O-methoxyethyl; LNA: locked nucleic acid; ENA: 2′-O, 4′-C-ethylene-bridged nucleic acid; 2′-F: 2′-fluoro; CeNA: cyclohexenyl nucleic acid; ANA: altritol nucleic acid; HNA: 1,5-anhydro hexitol nucleic acid; MNA: morpholino nucleic acid; PS: phosphorothioate; PNA: peptide nucleic acid; PMO: phosphorodiamidate morpholino oligomer.
Nucleobase modifications are not very common, as they impact the base-pairing properties of the AO. However, there is one naturally occurring nucleobase modification: the C-5 methyl substitution on pyrimidine nucleobases. This naturally occurring modification has been explored for its potential use in medicinal chemistry. Nucleobase modifications are not commonly seen in exon-skipping AOs. A detailed review of the various chemical modifications can be found elsewhere [32].

One of the first AOs to be used in exon-skipping experiments was 2′-OMe-PS [33]. These AOs have a phosphorothioate (PS) backbone with a 2′-O-methyl modified sugar moiety. The 2′-OMe-PS AOs were first used to show exon skipping in the dystrophin transcripts in cultured primary cells from mdx dystrophic mice [34]. Interestingly, Lu et al. demonstrated that 2′-OMe-PS AOs injected locally in skeletal muscles or via the tail vein showed efficient exon skipping and restored dystrophin protein levels [35,36]. This work led to the discovery of drisapersen, a 2′-OMe-PS AO drug targeting exon 51 that demonstrated significant restoration of the dystrophin protein and forbearance in systematic clinical trials [37].

Another chemical modification that has been studied is the use of tricyclo-DNA (tcDNA) to induce exon skipping in the treatment of DMD [38,39] or to induce exon inclusion for the treatment of SMA [40]. tcDNA deviates from natural DNA by the presence of three additional carbon atoms between c5′ and c3′, to which a cyclopropane unit is attached to further enhance structural stability [41,42]. tcDNA chemistry displays interesting properties for neuromuscular disorder therapy due to its quick uptake in cardiac and respiratory muscles [43]. This chemistry also has the unique property of being capable of crossing the blood-brain barrier at low levels after systemic uptake [38–40].

Locked nucleic acid (LNA)-modified AOs have a methylene bridge connecting 2′-O and 4′-C of the ribose sugar [44,45]. LNA AOs were shown to induce effective exon 46 skipping in exon 45-deleted DMD patient cells. LNA AOs showed effective skipping and exhibited high specificity due to the high target affinity of the 14-mer LNA AO [46]. Peptide nucleic acids (PNA) have an N-(2-aminoethyl)-glycine unit attached to the nucleobase and show good affinity to both DNA and RNA targets with high specificity [47]. In a DMD model system, PNA oligonucleotides, along with other PNA conjugates such as the trans activator of transcription protein (TAT protein), adeno-associated virus (AAV) 6 and AAV-8 functional domain and muscle-specific peptides were used to induce exon 23 skipping in vitro and in vivo. PNA AOs and PNA along with the conjugates effectively induced exon 23 skipping in both in vitro and in vivo models [48]. In another extended study, a 25-mer PNA targeting exon 23 showed better exon skipping than its 20-mer PNA counterpart [49].

Phosphorodiamidate morpholino oligomers (PMO) are made of DNA bases linked to a methylenemorpholine ring backbone attached through phosphorodiamidate groups. In general, PMOs are more effective in modulating splicing when compared with a corresponding 2′-OMe-PS AO [50]. In a direct comparison study in mdx mice between a 25-mer PMO and the same length 2′-OMe-PS AO, the PMOs induced better exon 23 skipping and showed higher levels of dystrophin protein recovery upon both systemic and local delivery than the corresponding 2′-OMe-PS AO [51]. In another comparison study, PMOs showed more exon 23 skipping in a mouse model than the 2′-OMe-PS AO [52]. However, in human exons, both PMO and 2′-OMe-PS AO indicated comparable data in vivo. In addition, PMOs might be less sequence-specific than 2′-OMe-PS AO [53]. More recently, the use of peptide-conjugated PMOs has emerged to facilitate better delivery of PMOs. Betts et al. showed that an arginine-rich cell-penetrating peptide conjugate effectively delivered PMOs to non-skeletal muscles. The delivery was quite efficient, as it increased heart activity and high dystrophin restoration. Their data also established that the PNA internalization peptides (Pip) sequence was efficient for PMO delivery [24,53]. In 2016, Exondys 51, a PMO drug for DMD developed by Sarepta Therapeutics, was FDA approved [54]. In 2019, another PMO drug, Vyondys 53, was also approved by the FDA, which was also developed by Sarepta Therapeutics [25]. The potential of various chemically modified oligonucleotide
chimeras has been explored in recent years to further improve the AO designs for enhanced splice switching [55–64].

4. Alternative Splicing in Cancer

Cancer is one of the leading causes of death worldwide. The traditional therapies for cancer such as chemotherapy, radiotherapy and surgery fail to address the fundamental molecular pathologies associated with the development of cancer and thus lead to inadequate treatment and cancer recurrence. One of the most recent advancements in the cancer treatment regimen is the development of targeted therapies. Evaluating the roles for cancer-related genes in the development of a tumor is a progressing field and has provided a number of viable targets for antisense therapy [65]. Specifically, in cancer, cell signaling pathways represent multiple targets. The most promising targets are the ones closely involved in key cancer-mediating processes, such as apoptosis, cell proliferation, angiogenesis and metastasis [65].

Most cancers are genetic diseases which are caused mainly due to aberrant changes in two main types of genes, i.e., proto-oncogenes and tumor suppressors [66]. Aberrant splicing of a proto-oncogene or tumor suppressor could impact a regulatory mechanism, resulting in cancer as opposed to the normal functioning of the proteins [10]. For example, cyclin D-binding Myb-like protein 1 (DMP1) is a tumor suppressor gene in breast cancer [67]. DMP1 splicing results in DMP1α, DMP1β and DMP1γ [68]. DMP1α acts as tumor suppressor by transcriptionally upregulating ADP ribosylation factor (ARF), initiating anti-tumorigenesis in a tumor protein p53 (P53)-dependent manner and causing apoptosis [69]. On the other hand, DMP1β has a proliferative oncogenic response that is P53-independent. DMP1β is overexpressed in around 60% of breast cancers with poor prognosis [68,69].

In addition to oncogenes and tumor suppressors, alternative splicing of normal genes or splicing regulators plays an important role in cancer. This alternative splicing either promotes or suppresses cancer growth depending on the isoform expressed [70]. The following examples of alternative splicing promote cancer when one isoform is expressed and impede cancer when the other isoform is expressed. Some of the genes that play a role in proliferation due to alternative splicing include ribosomal protein S6 kinase beta-1 (RPS6KB1), MAP kinase-interacting serine/threonine-protein kinase 2 (MKNK2), fibroblast growth factor receptor (FGFR), cyclin D1 (CCND1) and H-RAS. Aberrant splicing of BCL2-like 1 (BCL2L1), myeloid cell leukemia sequence 1 (MCL-1), fas cell surface death receptor (FAS), bridging integrator 1 (BIN1) and caspase 2 (CASP2) plays a role in cell death. Cancer cell metabolism is modified by alternative splicing of pyruvate kinase M1/2 (PKM) and bromodomain-containing 4 (BRD4) genes. Angiogenesis in cancer can be modulated by alternative splicing of vascular endothelial growth factor A (VEGFA). Specific isoforms of CD44, ENAH actin regulator (ENAH), Kruppel-like factor 6 (KLF6), receptor d’Origine nantais (RON) tyrosine kinase, and Rac family small GTPase 1 (RAC1) can promote cancer cell invasion and migration. In addition to these, isoforms of BIM and HER2 impart drug resistance in cancer cells [30,71–74].

5. Exon-Skipping AOs in Cancer

The development of nucleic acid-based therapeutics for cancer has gained prevalence in the past decades. Splice-modulating AOs have been used for suppressing the genes involved in the progression of cancer [75,76]. In this section the existing exon-skipping antisense oligonucleotide studies are discussed.

5.1. Breast Cancer

In 2018, there were about 2.1 million newly diagnosed breast cancer cases in females worldwide, accounting for about one in four cancer cases in women. Only 5–10% of breast cancers are attributed to hereditary factors [77]. In general, breast cancers are categorized based on the expression of estrogen receptor, progesterone receptor and the
human epidermal growth factor receptor 2 (HER2). Knowing the receptor status of cancer aids in providing specific treatment options. Approximately 25–30% of breast cancers have HER2 overexpression or amplification. Although conventional anti-HER2 therapy has achieved success in treating the HER2+ve subtype of breast cancer, the non-specific action of the HER2 inhibitors has limited the practicality of this approach [78–80]. So far, there are three studies elucidating the use of AO-mediated exon skipping in breast cancer. These studies mainly focus on the genes encoding epidermal growth factor receptors (EGFR), specifically HER2 and human epidermal growth factor receptor 4 (HER4).

A 2′-MOE-modified AO was used to induce skipping of exon 15 in the HER2 gene in SK-BR-3 breast cancer cells, leading to downregulation of HER2. Downregulation of HER2 results in upregulation of Δ15HER2, which is an inhibitor of HER2 (Table 1, No. 1). Δ15HER2 downregulated the full-length HER2 protein and reduced the transphosphorylation of HER3. These AOs served as a platform for the identification of the physiological role of Δ15HER2, a novel HER2 variant. In addition, administration of the AO inhibited the proliferation of the SK-BR-3 cells and induced apoptosis. This suggests that the 2′-MOE AO could be explored in the context of therapeutics [81]. In another in vitro study, a PNA targeting the intron-exon junction site of exon 19 of HER2 induced exon skipping in SK-BR-3 breast cancer cells and HeLa cervical cancer cell lines (Table 1, No. 2). Exon 19 codes for the ATP catalytic domain of HER2, leading to a functionally inactive HER2 protein in a dominant negative fashion. The PNA was used in this study could be a potential drug for therapeutic applications [82]. While current studies have investigated HER2 in a breast cancer context only, the HER2 oncogene is overexpressed in a variety of additional cancers as well, making a new drug widely applicable [83].

HER4, another member of the EGFR family, plays a diverse role in the development and progression of breast cancer [84]. LNAs targeting the intron-exon junction of exon 26 caused skipping of the exon and switched the splicing of HER4 from cytoplasmic domain 1 (CYT1) isoform to cytoplasmic domain 2 (CYT2) expression in HER4-expressing breast cancer cells (Table 1, No. 3). These AOs also inhibited the growth of the cancer cells.

5.2. Leukemia

As of 2018, the incidence rate of leukemia globally is about 2.4% and the mortality rate about 3.2% [86]. Treatment options for leukemia vary depending on the type. Apart from conventional treatments like chemotherapy, the use of monoclonal antibodies and gene inhibitors for acute lymphocytic and acute myeloid leukemia are prevalent [87,88].

Wilms tumor gene (WT1) overexpression is generally a characteristic of acute leukemias and is associated with poor prognosis [89]. WT1 is located on 11p13 and encodes a zinc finger motif-containing transcription factor. This transcription factor is involved in the regulation of differentiation and growth [90]. Expression pattern analysis revealed that WT1 is involved in the early stage of hematological cell differentiation [90]. An AO targeting exon 5 of WT1 showed an upregulation of thrombospondin, a target gene of WT1 in HL-60 cells (Table 1, No. 4). Upregulation of thrombospondin correlated with cell death in HL-60 cells. K562 cells were also sensitive to the WT1 AOs [90,91]. WT1 is not only overexpressed in leukemia, but also in a variety of other cancers, including breast cancer, prostate cancer and embryonal cancers [92]. This suggests exploring the therapeutic benefits of these AOs in leukemia and other cancers.

Terminal deoxynucleotidyl transferase (TdT) is an intracellular protein which is expressed by lymphocytes in the bone marrow and thymus [93]. High levels of TdT are characteristics of certain lymphoblastic leukemias. TdT is now a well-established diagnostic marker for acute lymphocytic leukaemia [93,94]. In an in vitro study, 16-mer PNAs were used to target the 5′ and 3′ junctions of intron 7 of TdT in Molt-4 acute lymphoblastic
leukemia cells. The specificity of the AO was confirmed by comparing it to a sequence with two base mismatches. Reverse transcriptase PCR (RT-PCR) showed inclusion of intron 7 and subsequently skipping of exon 7 in the TdT gene, leading to significantly reduced TdT expression levels (Table 1, No. 5). Downregulation of TdT was accompanied with an increase in the rate of apoptosis [95].

5.3. Melanoma

The global maximum incidence rate and mortality rate of melanoma is about 4.2% and 1.4%, respectively. Although melanomas are not a leading cause of cancer deaths, the incidence rates of melanoma have significantly increased in the past 50 years [96]. While inactivation of p53 is a common event in most cancers, melanomas with TP53 mutations are very rare. However, the MDM4 regulator of p53 (MDM4) is highly upregulated in most melanomas and promotes the survival of melanoma cells by antagonizing the pro-apoptotic function of p53. This makes MDM4 a key therapeutic target for melanoma [97]. Overexpression of MDM4 is caused by inclusion of exon 6, which leads to the expression of a full length MDM4. MDM4 exon 6 acts as nonsense-mediated decay (NMD) “NMD switch” [98]. Though this alternative splicing event is regulated by a number of factors, it was noted that the oncoprotein serine- and arginine-rich splicing factor 3 (SRSF3) is the key initiator of exon 6 inclusion in MDM4 [98]. In this study, a morpholino AO flanking the exon-intron junction of exon 6 and overlapping the SRSF3 binding site inhibited cancer growth both in in vitro and in vivo melanoma models (Table 1, No. 6). It also sensitized the cells to MAPK-targeting therapeutics, which is a common treatment strategy for melanoma. Similar results were seen in lymphoma models as well. As MDM4 is overexpressed in additional types of cancer, this strategy may be applicable beyond melanoma [98].

Table 1. Schematic representation of the six distinct studies on developing splice-modulating AOs targeting cancers. Among these AOs, (1) SSO111, (2) Acr-PNA 2794, (3) SSOe26, and (6) morpholino MDM4 inhibited overexpression of oncogenes by inducing exon skipping, thus producing non-functional variants or leading to nonsense-mediated decay (NMD) of mRNA, while (5) PNA 4577, 4578, 4580 and 4581 predominantly induced intron retention, resulting in the production of non-functional variants. Besides, (4) ASWT1exon5 induced RNase H-mediated degradation of longer transcripts, thus increasing the proportion of naturally occurring, shorter transcripts which exclude an important exon. 2′-MOE, 2′-O-methoxyethyl; 2′-O-methyl; PNA, peptide nucleic acid; LNA, locked nucleic acid; PS, phosphorothioate; PMO, phosphorodiamidate morpholino oligomer.

| No. | AO | Ref. |
|-----|-----|------|
| 1   | SSO111 | [81] |
| 2   | Acr-PNA 2794 | [82] |
| 3   | SSOe26 | [81] |
| 4   | ASWT1exon5 | [81] |
| 5   | PNA 4577, 4578, 4580 and 4581 | [81] |
| 6   | Morpholino MDM4 |[81] |
6. Antisense Oligos in Clinical Trials

A comprehensive list of AOs in cancer clinical trials has been enumerated in Table 2.

6.1. Apatorsen/OGX-427

Apatorsen is a 20mer AO harboring a 2′-MOE-PS modification. This AO effectively reduced the expression of heat shock protein 27 (Hsp27), an adenosine-independent cytoprotective chaperone overexpressed in cancers. A dose escalation phase I trial of apatorsen carried out in patients with advanced cancers revealed that a maximum dose of 1000 mg can be tolerated [99]. This drug, in combination with other chemo drugs, improved the survival of patients with poor prognostic advanced cancers [100,101]. In another trial, apatorsen with chemotherapy did not improve the overall and progression-free survival of metastatic pancreatic cancer, non-squamous non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and squamous cell lung cancer patients [102–105].
6.2. AZD4785

AZD4785 is a 2′-4′ constrained ethyl (cEt) modified AO that binds to the 3′ untranslated region (3′UTR) of Kirsten rat sarcoma virus (KRAS) mRNA, leading to RNase H-mediated degradation. This cEt modification enables AO uptake by cells without any transfection reagent [106]. A phase 1 study investigated the safety and efficacy of AZD4785 in KRAS-driven advanced solid tumors. The results of this study are published on the AstraZeneca website [107].

6.3. AZD5312/AR

The 2.5 generation AO AZD5312 is a PS cEt AO that binds to androgen receptor (AR) mRNA. A phase I dose escalation study of AZD5312 revealed that 900 mg is the maximum tolerated dose in patients with androgen receptor-driven advanced tumors [108]. This study did not show a favorable reduction in AR expression. Another phase I/II study is currently ongoing wherein AZD5312 is administered in combination with enzalutamide in advanced prostate cancer patients [109].

6.4. AZD9150/ISIS 481464/ISIS-STAT3Rx/Danvatirsen

Danvatirsen is a 16mer, 3-10-3 modified gapmer containing ten PS-modified deoxynucleotides flanked by three cEt nucleotides. Danvatirsen regulates the expression of signal transducer and activator of transcription 3 (STAT3). Phase I studies of danvatirsen in lymphoma and other advanced malignancies as a monotherapy and in combination with chemotherapies revealed the safety and efficacy of this AO [110–112]. Currently, danvatirsen is under phase II trials in advanced tumors to evaluate the tolerability and efficacy of the combination of drugs.

6.5. BP1001

BP1001 is synthesized using DNAbilize technology and is a dioleoylphosphatidylcholine (DOPC) lipid-encapsulated P-ethoxy modified AO. BP1001 targets growth factor receptor-bound protein 2 (Grb2), which is involved in oncogenic tyrosine kinase signal transduction. A dose escalation and expansion phase I clinical trial in advanced hematological cancers showed that BP1001 is well tolerated at 90 mg/m² concentration [113]. Phase II trials are currently recruiting acute myeloid leukemia (AML) patients to test the efficacy of BP1001 in combination with chemotherapeutic drugs such as venetoclax and decitabine.

6.6. C-Myb AS ODN/G4460/LR3001

The master regulator transcription factor c-Myb plays a major role in hematopoietic malignancies [114]. G4460 is a PS-modified 24mer AO that binds to codons 2 to 9 of c-Myb mRNA [115]. A phase II study was carried out in chronic myelogenous leukemia (CML) patients to study the efficacy of G4460 in combination with chemotherapy followed by bone marrow transplantation [116]. A phase I trial of c-Myb AO administered G4460 as a continuous intravenous infusion to patients with advanced hematological malignancies. The efficacy of c-Myb AO could not be concluded from these studies.

6.7. EZN-2968/RO7070179/SPC2968

The LNA-modified EZN-2968 is a 16mer AO that is complementary to the α subunit of hypoxia-inducible factor-1 alpha (HIF-1α). This third-generation AO is modified with LNA at bases 1 to 3 and 13 to 15, and DNA at 4 to 12 and 16 [117]. This AO entered phase I clinical trials to study its maximum dose and safety in patients with advanced cancers. EZN-2968 was well tolerated at a maximum dose of 4.1 mg/kg/day with no dose-limiting toxicities [118]. Another phase I trial carried out in patients with refractory tumors revealed reduced levels of HIF-1α post treatment [119]. The efficacy of EZN-2968 was tested in a phase I trial with hepatocellular carcinoma (HCC) patients unresponsive for systemic therapy. This study revealed that 10 mg/kg EZN-2968 was well tolerated in HCC patients
with either stable disease or partial responses [120]. However, these studies need to be validated in more patients to estimate the effectiveness of this AO.

6.8. G3139/Oblimersen/Genasense

Oblimersen is a 18mer PS AO that binds to the first six codons of B cell lymphoma 2 (Bcl2) mRNA. It is tested as a monotherapy or in combinations to study its safety and efficacy in different cancer types. The first Phase I/II clinical trial of oblimersen was started in 1997 as a combination therapy with docetaxel in advanced solid tumors [121]. The next phase I study was carried out in refractory acute myeloid/lymphoblastic leukemia patients alongside fludarabine, cytarabine and filgrastim, which revealed that oblimersen is effective in combination with chemotherapy [122]. The following year, oblimersen combination therapy testing was initiated in phase I and II clinical trials in small cell lung cancer (SCLC), AML, and colorectal cancer (CRC) [123–125] and in phase III trials for malignant melanoma and multiple myeloma [126,127]. These studies showed that the combination therapies for respective cancers along with oblimersen were well tolerated and the adverse events of the combinations were similar to chemotherapy alone. The phase III trial with oblimersen in advanced multiple myeloma patients did not have any significant improvement in time to tumor progression when compared to dexamethasone treatment alone [127].

A phase I study of oblimersen combination therapy in extensive stage SCLC revealed that an oblimersen and chemotherapy combination had a better response rate and time to tumor progression [128]. A phase I/II trial in chronic lymphocytic leukemia (CLL) patients with oblimersen monotherapy was reported to have modest activity [129], and hence, a phase III trial was carried out in combination with fludarabine/cyclophosphamide. A five-year follow-up of this phase III trial showed improved survival in 45% of responding patients and 50% reduced death in oblimersen combination treatment [130]. A phase I and II trial of oblimersen with chemotherapy showed improved outcomes, which led to a phase III trial in AML. Follow-up studies showed no significant difference in disease-free survival in patients treated with oblimersen in addition to chemotherapy [131]. A similar outcome was seen in a phase III trial of oblimersen and dacarbazine in advanced melanoma [132]. Even though there were some improvements in the oblimersen treatment, it did not improve the overall progression or disease-free survival of these cancer patients.

6.9. GTI-2040

GTI-2040 is a 20mer PS AO that binds to the R2 subunit of ribonucleotide reductase (RNR). A dose escalation phase I study of GTI-2040 in patients with advanced cancers revealed that 185 mg/m²/day is well tolerated as a monotherapy [133]. A phase I/II trial of GTI-2040 with capecitabine in advanced renal cell carcinoma (RCC) patients was not successful, and hence, it was not recommended to proceed further in RCC [134]. Phase I/II studies of GTI-2040 in combination with chemotherapies were carried out in different cancers, including metastatic breast cancer, AML, NSCLC, metastatic solid tumors and CRPC [135–139]. From these clinical trials, it was evident that GTI-2040 performed better as a single agent therapy than in combination with other drugs [140].

6.10. ISIS 3521

ISIS 3521 is a PS-modified 20mer oligo that is complementary to the 3′UTR of protein kinase C alpha (PKC-α). A dose escalation phase I study of ISIS 3521 in advanced cancer patients revealed 6 mg/kg as a recommended dosage [141]. A combination of ISIS 3521, gemcitabine and carboplatin/cisplatin was used in phase II/III clinical trials of advanced NSCLC patients. This study showed that the combination therapy did not improve the response rate or survival of advanced NSCLC patients [142].

6.11. ISIS 5132

Human c-Raf kinase targeting ISIS 5132 is a first-generation PS-modified AO with a length of 20 bases. The maximum tolerated dose was observed to be 4 mg/kg/day during
a phase I trial in advanced cancer patients [143]. A phase II trial of ISIS 5132 in advanced ovarian cancer patients showed no clinical activity [144]. These trials concluded that ISIS 5132 cannot be used as a single agent therapy. A phase II study of a combination of ISIS 3521 and ISIS 5132 was carried out in metastatic CRC patients. This study also did not show any positive clinical outcome [145].

6.12. LErafAON

LErafAON is a c-Raf-1-targeting AO ISIS 5132 encapsulated in a cationic liposome; it is about 400 nm diameter. A phase I trial of LErafAON in advanced solid tumors resulted in dose-dependent and dose-independent adverse events [146]. Another phase I trial was carried out in advanced cancer patients using a combination of LErafAON alongside radiotherapy. This study reported similar adverse events as the previous study and hence concluded that the liposomal preparations need to be modified [147].

6.13. OGX-011

Custirsen/OGX-011 is a second-generation 2′-MOE PS-modified AO that is complementary to clusterin mRNA. A phase I dose escalation study of OGX-011 performed in prostate cancer patients discovered that 640 mg was the optimal dosage [148]. Following this study, a combination therapy phase I clinical trial was carried out in patients with advanced cancer. It was observed that overall toxicity was moderate with increased gastrointestinal effects with an increase in OGX-011 concentration [149]. In a phase II clinical trial with metastatic breast cancer patients, an OGX-011 and docetaxel combination was well tolerated, and it did not have any adverse events other than the docetaxel-mediated ones. Additionally, there was not much difference in the response rate between the mono- and combination therapy [150]. A phase II study in castration-resistant prostate cancer patients with OGX-011 in combination with chemotherapy showed improved clinical outcomes [151,152]. A large phase III clinical trial of OGX-011 and chemo combination therapy in castration-resistant prostate cancer patients did not show any improved outcomes relevant to OGX-011 [153].
Table 2. List of antisense oligonucleotides in clinical trials.

| No | Drug Name          | Ref. | Target                   | Condition                                                                 | Clinical Trial Number | Development Stage | Chemistry | Chem Ref. |
|----|--------------------|------|--------------------------|--------------------------------------------------------------------------|------------------------|-------------------|-----------|-----------|
| 1  | Apatorsen (OGX-427)| [99] | Hsp27                    | Prostate, ovarian, NSCLC, breast or bladder cancer                      | NCT00487786           | Phase I           | 2′-MOE PS       |
|    |                    |      |                          | Prostate cancer                                                          | NCT01120470           | Phase II          |           |           |
|    |                    |      |                          | Urologic neoplasms                                                       | NCT01681433           | Phase II          |           |           |
|    |                    |      |                          | Urothelial carcinoma                                                    | NCT01454089           | Phase II          |           |           |
|    |                    |      |                          | Non-squamous NSCLC                                                      | NCT01780545           | Phase II          |           |           |
|    |                    |      |                          | Advanced squamous cell lung cancers                                     | NCT01829113           | Phase II          |           |           |
|    |                    |      |                          | Pancreatic cancer                                                       | NCT01844817           | Phase II          |           |           |
| 2  | AZD4785            | [104]| KRAS                    | NSCLC/advanced solid tumors                                             | NCT03101839           | Phase I           | 2′-4′ cEt       |
|    |                    |      |                          | Androgen receptor-dependent advanced solid tumors                      | NCT02423590           | Phase II          |           |           |
|    |                    |      |                          | Prostate cancer/solid tumors                                            | NCT02144051           | Phase I           | PS cEt         |
|    |                    |      |                          | DLBCL/NHL                                                               | NCT02549651           | Phase Ib/II       |           | [108]     |
|    |                    |      |                          | HCC and metastasis                                                      | NCT03394144           | Phase I           |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
| 3  | AZD5312 (ARRx)     | [107]| Androgen receptor        | Androgen receptor-dependent advanced solid tumors                      | NCT00780545           | Phase I           | 2′-4′ cEt       |
|    |                    |      |                          | Prostate cancer/solid tumors                                            | NCT00780545           | Phase I           | PS cEt         |
|    |                    |      |                          | DLBCL                                                                  | NCT00780545           | Phase I           |           |           |
|    |                    |      |                          | HCC                                                                    | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid tumors                                                  | NCT02549651           | Phase Ib          |           | [112]     |
| 4  | AZD9150            | [109]| STAT3                   | Advanced solid tumors                                                  | NCT0300505            | Phase I           | cEt gapmer     | Ongoing   |
|    |                    |      |                          | Muscle-invasive bladder cancer                                          | NCT01563302           | Phase I/II        |           | [110]     |
|    |                    |      |                          | Metastatic NSCLC                                                        | NCT03527147           | Phase I           |           | [155]     |
|    |                    |      |                          | NSCLC                                                                  | NCT01839604           | Phase I           |           | [156]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT03394144           | Phase I           |           | [157]     |
|    |                    |      |                          | DLBCL                                                                  | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT02549651           | Phase Ib          |           | [112]     |
| 5  | BP1001             | [113]| Grb2                    | Recurrent adult AML/ALL, Myelodysplastic syndrome                       | NCT00487786           | Phase I           | DNAAbilize® technology | Ongoing   |
|    |                    |      |                          | Ph1-positive CML                                                        | NCT01120470           | Phase II          |           |           |
|    |                    |      |                          | Solid tumors                                                            | NCT01681433           | Phase II          |           |           |
|    |                    |      |                          | AML                                                                    | NCT01454089           | Phase II          |           |           |
|    |                    |      |                          | Metastatic NSCLC                                                        | NCT01780545           | Phase II          |           |           |
|    |                    |      |                          | NSCLC                                                                  | NCT01829113           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
|    |                    |      |                          | Advanced solid malignancies                                            | NCT01844817           | Phase II          |           |           |
| 6  | c-myb AS ODN       | [116]| c-myb                   | Leukemia                                                                | NCT00780545           | Phase I           | PS          | Ongoing   |
|    |                    |      |                          | Hematologic malignancies                                               | NCT02000259            | Phase II          |           |           |
|    |                    |      |                          | Carcinoma/lymphoma                                                     | NCT00466583           | Phase I           |           |           |
| 7  | EZN-2968           | [119]| HIF-1                   | Liver metastases/neoplasms                                             | NCT01120288           | Phase I           | LNA         | Ongoing   |
|    |                    |      |                          | HCC                                                                    | NCT02564614           | Phase I           |           |           |
| No | Drug Name       | Target | Condition                          | Clinical Trial Number | Development Stage | Chemistry | Ref. |
|----|----------------|--------|------------------------------------|-----------------------|-------------------|-----------|------|
|    | G3139 (Oblimersen) | Bcl-2  |                                    |                       |                   | PS        |      |
| 8  |                |        | Waldenström                        | NCT00062244           | Phase 1           |           | [159]|
|    |                |        | Macroglobulinemia                  | NCT00079131           | Phase 2           |           | [160]|
|    |                |        | Merkel cell carcinoma              | NCT0003103            | Phase 2           |           | [121]|
|    |                |        | Solid tumors                       | NCT0054548            | Phase 1           |           | [161]|
|    |                |        | Relapsed or refractory solid tumors| NCT0039481            | Phase 1           |           | [161]|
|    |                |        | Leukemia (AML or ALL)              | NCT0004862            | Phase 1           |           | [122]|
|    |                |        | AML                                | NCT00039117           | Phase 1           |           | [163]|
|    |                |        | CRC                                | NCT0004870            | Phase 2           |           | [124]|
|    |                |        | Prostate cancer                    | NCT00058522           | Phase 2           |           | [164]|
|    |                |        | HCC                                | NCT00047229           | Phase 2           |           | [166]|
|    |                |        | Recurrent SCLC                     | NCT0005032            | Phase 1           |           | [123]|
|    |                |        | Extensive stage SCLC               | NCT0017251            | Phase 1           |           | [128]|
|    |                |        | CML                                | NCT00042978           | Phase 2           |           | [128]|
|    |                |        | NHL                                | NCT00049192           | Phase 2           |           | [167]|
|    |                |        | Recurrent B-cell NHL               | NCT0086944            | Phase 2           |           | [168]|
|    |                |        | CLL                                | NCT00054639           | Phase 2           |           | [168]|
|    |                |        | Metastatic RCC                     | NCT00078234           | Phase 1           |           | [169]|
|    |                |        |                                    | NCT0021749            | Phase 1           |           | [129]|
|    |                |        |                                    | NCT0024440            | Phase 3           |           | [130]|
|    |                |        |                                    | NCT0059813            | Phase 2           |           | [170]|
Table 2. Cont.

| No | Drug Name | Target | Condition | Clinical Trial Number | Development Stage | Chemistry       | Ref. |
|----|-----------|--------|-----------|------------------------|-------------------|-----------------|------|
|    | GTI-2040  | R2 component of RNR | Advanced esophageal, gastro-esophageal junction and gastric cancer | NCT00064259 | Phase 1 | PS | [171] |
|    |           |        | Melanoma | NCT00409383 | Phase 1 | Unknown | [172] |
|    |           |        | NSCLC    | NCT00030641 | Phase 3 |Not applicable | Ongoing |
|    |           |        | Multiple myeloma and plasma cell neoplasm | NCT0049374 | Phase 2 | [173] |
|    |           |        | DLBCL    | NCT00017602 | Phase 3 | [126] |
|    |           |        | Breast cancer | NCT00070083 | Phase 1 | [174] |
|    |           |        | AML      | NCT00565058 | Phase 1 | [135] |
|    |           |        | NSCLC    | NCT00070343 | Phase 2 | [136] |
| 9  | 9 GTI-2040 | R2 component of RNR | Multiple myeloma and plasma cell neoplasm | NCT0049374 | Phase 2 | [174] |
|    |           |        | NSCLC    | NCT00030641 | Phase 3 | [127] |
|    |           |        | Multiple myeloma and plasma cell neoplasm | NCT00017602 | Phase 3 | [174] |
|    |           |        | NSCLC, prostate cancer, or other solid tumors | NCT0074022 | Phase 3 | [175] |
|    |           |        | CRC or other solid tumors | NCT00084643 | Phase 1 | [136] |
|    |           |        | Prostate cancer | NCT0087165 | Phase 2 | [137] |
|    |           |        | Metastatic or unresectable solid tumors | NCT00078962 | Phase 1 | [138] |
|    |           |        | NSCLC/ melanoma (skin) | NCT0003989 | Phase 2 | [139] |
|    |           |        | NSCLC    | NCT00017407 | Phase III | [140] |
| 10 | ISIS 3521 | Pkc-Alpha | Acute leukemia, high-grade myelodysplastic syndromes, or refractory or blastic phase CML | NCT00459212 | Phase 1 | PS | [176] |
|    |           |        | NSCLC    | NCT00042679 | Phase II | PS | [177] |
|    |           |        | NSCLC    | NCT00034268 | Phase III | PS | [178] |
| 11 | ISIS 5132 | C-raf | Ovarian cancer | NCT0003892 | Phase II | PS | [179] |
|    | ISIS 3521 + ISIS 5132 | Pkc-Alpha | C-raf | NCT00003236 | Phase II | [179] |
| 12 | LErafAON | Raf-1 | Advanced solid tumors | NCT00024661 | Phase I | Liposome encapsulated PS | [180] |
|    |           |        | NSCLC    | NCT00100672 | Phase I | [179] |
|    |           |        | NSCLC    | NCT00024648 | Phase I | [180] |
Table 2. Cont.

| No  | Drug Name | Target          | Condition       | Clinical Trial Number | Development Stage | Chemistry       | Ref.  |
|-----|-----------|-----------------|-----------------|-----------------------|-------------------|----------------|-------|
| 14  | OGX-011   | Clusterin       | Prostate cancer | NCT01497470           | Phase I           | 2′-MOE PS      |       |
|     |           |                 |                 | NCT00138658           | Phase I/II        |                | [181] |
|     |           |                 |                 | NCT01630733           | Phase III         |                | [182] |
|     |           |                 |                 | NCT00054106           | Phase I           |                | [181] |
|     |           |                 |                 | NCT00258388           | Phase II          |                | [151] |
|     |           |                 | Prostate cancer | NCT0138918            | Phase II          | 2′-MOE PS      | [181] |
|     |           |                 |                 | NCT003227340          | Phase II          |                | [152,183] |
|     |           |                 |                 | NCT01578655           | Phase III         |                | [153] |
|     |           |                 |                 | NCT01188187           | Phase III         |                | [184,185] |
|     |           |                 | Breast cancer   | NCT00258375           | Phase II          |                | [150] |
|     |           |                 | Solid tumors    | NCT00471432           | Phase I           |                | [149] |

Hepatocellular carcinoma—HCC; small cell lung cancer—SCLC; non-small cell lung cancer—NSCLC; diffuse large B cell lymphoma—DLBCL; non-Hodgkin’s lymphoma—NHL; colorectal cancer—CRC; acute myeloid leukemia—AML; acute lymphoblastic leukemia—ALL; chronic myelogenous leukemia—CML; chronic lymphocytic leukemia—CLL; renal cell carcinoma—RCC.
7. Modes of AO Delivery

The effectiveness of an AO depends primarily on the extent to which the AO diffuses through cells. AOs require an appropriate delivery system to facilitate their entry into the cytoplasm and/or the nucleus. One of the key issues faced is the process of endosomal escape. Delivery systems employed for AOs are constantly being updated to ensure optimal delivery of the AOs [186–188]. In this section, some of the delivery modes used, such as liposome- and lipoplex-based delivery systems, dendrimers, polymers, peptides, macrophages, electroporation, and light are discussed in brief.

Lipidic delivery systems are the most commonly used delivery vehicles in AO transport. Lipoplexes are a combination of cationic liposomes, neutral lipids and nucleic acids which ease the intracellular delivery of AOs [189]. The most widely used cationic lipids include DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate) and DOTMA (N-[l-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium) [190,191]. Lipoplexes enter cells through endocytosis. The neutral lipid dioleylphosphatidylethanolamine (DOPE) facilitates the release of the AOs through fusion and disruption of the endosomal complex [192]. A detailed review on lipid-based delivery vehicles can be found elsewhere [193]. There are many commercially available lipid-based delivery agents which have been studied extensively and have been shown to improve AO delivery [194].

Dendrimers are a supermolecular delivery system which can be synthesized with various functional groups, making them a versatile non-viral particle delivery system [195]. The commonly used dendrimer polyamidoamine (PAMAM) starburst possess a hydrocarbon core, charged amino groups and a controlled chemistry which is suitable for anionic AO delivery [195]. Belinshka et al. elucidated the use of dendrimers as a delivery system for AOs in cells that express luciferase. This study showed around 25–50% reduction of baseline luciferase activity, indicating the effectiveness of dendrimer-based delivery of AOs [196].

Polymers are also employed as delivery vehicles. Biodegradable polymers can offer sustained release of AOs. Poly-L-lysine is one of the first studied cationic polymers used for in vivo gene transfer [197]. Polylactides and copolymers of lactic acid and glycolic acid P(LA-GA) are the most commonly studied polymers; these polymers facilitate the delivery of AOs at a controlled pace and offer nuclease resistance [198,199]. P(LA-GA) has also shown effective transfection of AOs when compared with free AO uptake [200]. Hydrogels are hydrophilic polymers that form three-dimensional networks via chemical or physical crosslinks. Hydrogels mediate the sustained release of AOs in response to pH, concentration differences of analyte ionic strength electric fields or temperature [201]. A cationic hydrogel made of c-agarose coupled with AO against tumor necrosis factor alpha (TNF-α) showed high target affinity to the spleen and alleviated inflammation in arthritis animal models [202]. Lou et al. showed that a poly [1-vinyl-2-pyrrolidinone-co-(2-hydroxyethyl methacrylate)] hydrogel effectively delivered AOs to the specific target [203].

Peptide-based delivery vectors facilitate the delivery of AOs via endocytosis. Cell penetrating peptide (CPP) facilitates intracellular uptake unescorted [204]. TAT derived from HIV and penetratin from antennapedia homeodomain were the first CPPs used [205,206]. Amphiphilic anionic peptides like E5CA are able to effectively deliver AOs to the cytosol and nucleus [207]. CPPs have found applications in both in vitro and in vivo studies [208].

Novak et al. have elucidated a fairly new approach to deliver AOs via macrophages. Inflammatory cells work as a depot for the administered AOs, which are then released along with the damage repair protein and are readily available for use by the regenerating cells. This mode of AO delivery has been explained clearly in a DMD system, which improves site-specific delivery of the AO [209]. Exosomes are extracellular microvesicles which are about 40–100 nm in diameter [210]. Initially thought to be insignificant in cellular functioning, exosomes have now been identified to play major roles in systemic cell-cell communication [211,212]. In spite of their nanoscale, exosomes can encapsulate bioactive molecules in a single lipid membrane [213]. Exosomes are also highly cell type-specific and hence are perfect candidates for the specific delivery of nucleic acids. [214]. For example,
an LNA-modified AO for the suppression of miR34a successfully inhibited chondrocyte growth in osteoarthritis treatment [215].

Electroporation uses an externally applied electric field to create pores in the cell membrane when facilitating the entry of the AOs into the cells. Electroporation is a localized mode of AO delivery to the cells. Zewert et al. and Reigner et al. showed that fluorescence-labelled AOs against specific targets entered cells effectively through electroporation [216,217]. In another study, electroporation of AOs against proto-oncogene c-myc yielded specific suppression of c-myc [218]. Reigner et al. also showed effective transdermal delivery of phosphorothioate AOs in vivo [219].

Light-triggered delivery of AOs is a new technique established in the past decade. Fluorescent labelled AOs are generally conjugated with protein VP22 obtained from herpes simplex virus. This AO-protein complex is known as a vectosome. This vectosome reaches the cytoplasm and can be triggered by light, which releases the AO and the protein complex [220–222]. In vivo intravitreal injection of the vectosomes followed by transcleral illumination allowed delivery of AOs to retinal and RPE cells [222]. Recently, light-mediated delivery was carried out by complexing AOs with a thermosensitive liposome that releases the AOs upon light exposure, which showed high transfection efficiency [223].

Ultrasound-mediated AO delivery is another physical method that uses ultrasound waves of an optimal frequency. The AOs are generally delivered into the system using microbubbles, which then burst open by a localized application of ultrasound waves [224,225]. Negishi et al. elucidated this approach in a DMD mouse model (mdx) where a PEG-modified bubble liposome with ultrasound contrast gas was used to deliver the specific PMO [226].

8. Conclusions

The studies elucidated in this review reveal that antisense-mediated splice-switching strategy can be effectively used to change the expression of oncogenes and thereby control tumor growth in cancer models. A major drawback in the development of antisense drugs is site-specific delivery and stability. With the advent of new delivery techniques and chemical modifications, this caveat can likely be overcome in the future. Recent studies have also shown that chemically modifying the AOs increased the stability and the binding affinity of the AOs. Furthermore, these AOs were more cost effective with reduced cytotoxicity. This has paved the way for more targets to be explored that underpin a plethora of diseases, taking a step further in finding a possible cure. Antisense technology has progressed rapidly in the past two decades and has now emerged as a highly explored therapeutic strategy that is less or non-toxic and more efficacious.

Author Contributions: Conceptualization, R.N.V. and P.R.; writing—original draft preparation, P.R. and A.A.B.; writing—review and editing, P.R., A.A.B., S.C., S.D.D. and R.N.V.; supervision, R.N.V. and S.D.D. All authors have read and agreed to the published version of the manuscript.

Funding: P.R. thanks the Murdoch International Postgraduate Studentship (MIPS) funding scheme of Murdoch University. A.A.B. acknowledges the Commonwealth Government of Australia and Forrest Research Foundation for the scholarship. R.N.V. acknowledges the funding provided by the McCusker Charitable Foundation and the Perron Institute for Neurological and Translational Science.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Fackenthal, J.D.; Godley, L.A. Aberrant RNA splicing and its functional consequences in cancer cells. Dis. Models Mech. 2008, 1, 37–42. [CrossRef] [PubMed]
2. Johnson, M.B.; Kawasawa, Y.I.; Mason, C.E.; Krsnik, Ž.; Coppola, G.; Bogdanović, D.; Geschwind, D.H.; Mane, S.M.; State, M.W.; Šestan, N. Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron 2009, 62, 494–509. [CrossRef] [PubMed]
3. Siva, K.; Covello, G.; Denti, M.A. Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther. 2014, 24, 69–86. [PubMed]
4. Johnson, J.M.; Castle, J.; Garrett-Engele, P.; Kan, Z.; Loerch, P.M.; Armour, C.D.; Santos, R.; Schadt, E.E.; Stoughton, R.; Shoemaker, D.D. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. *Science* 2003, 302, 2141–2144.

5. Clark, T.A.; Schweitzer, A.C.; Chen, T.X.; Staples, M.K.; Lu, G.; Wang, H.; Williams, A.; Blume, J.E. Discovery of tissue-specific exons using comprehensive human exon microarrays. *Genome Biol.* 2007, 8, R64. [CrossRef]

6. Anna, A.; Monika, G. Splicing mutations in human genetic disorders: Examples, detection, and confirmation. *J. Appl. Genet.* 2018, 59, 253–268. [CrossRef] [PubMed]

7. Dhir, A.; Buratti, E. Alternative splicing: Role of pseudoexons in human disease and potential therapeutic strategies. *FEBS J.* 2010, 277, 841–855. [CrossRef] [PubMed]

8. Weir, B.; Zhao, X.; Meyerson, M. Somatic alterations in the human cancer genome. *Cancer Cell* 2004, 6, 433–438. [CrossRef]

9. Mendelsohn, J.; Howley, P.; Israel, M.; Gray, J.; Thompson, C. *The Molecular Basis of Cancer*; Saunders Elsevier: Philadelphia, PA, USA, 2008.

10. Wang, B.-D.; Lee, N.H. Aberrant RNA splicing in cancer and drug resistance. *Cancers* 2018, 10, 458. [CrossRef] [PubMed]

11. Gleave, M.E.; Monia, B.P. Antisense therapy for cancer. *Nat. Rev. Cancer* 2005, 5, 468–479. [CrossRef] [PubMed]

12. Arechavala-Gomeza, V.; Khoo, B.; Aartsma-Rus, A. Splicing Modulation Therapy in the Treatment of Genetic Diseases. *Appl. Clin. Genet.* 2014, 7, 243–252.

13. Chen, S.; Sbuh, N.; Veedu, R.N. Antisense oligonucleotides as potential therapeutics for Type 2 Diabetes. *Nucleic Acid Ther.* 2021, 31, 39–57. [CrossRef] [PubMed]

14. Crooke, S.T.; Liang, X.H.; Baker, B.F.; Crooke, R.M. Antisense technology: A review. *Nat. Rev. Drug Discov.* 2003, 2, 23–30. [CrossRef] [PubMed]

15. Bennett, C.F. Therapeutic Antisense Oligonucleotides Are Coming of Age. *Annu. Rev. Med.* 2019, 70, 307–321. [CrossRef] [PubMed]

16. Roberts, T.C.; Langer, R.; Wood, M.J.A. Advances in oligonucleotide drug delivery. *Nat. Rev. Drug Discov.* 2020, 19, 673–694. [CrossRef]

17. Le, B.T.; Raguraman, P.; Kosbar, T.R.; Fletcher, S.; Wilton, S.D.; Veedu, R.N. Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. *Mol. Ther.-Nucleic Acids* 2019, 14, 142–157. [CrossRef] [PubMed]

18. Kushner, D.M.; Silverman, R.H. Antisense cancer therapy: The state of the science. *Curr. Opin. Mol. Ther.* 2018, pp. 289–305. [CrossRef]

19. Chan, J.H.; Lim, S.; Wong, W.F. Antisense oligonucleotides: From design to therapeutic application. *Clin. Exp. Pharmacol. Physiol.* 2006, 33, 533–540. [CrossRef] [PubMed]

20. Kole, R.; Krainer, A.R.; Altman, S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. *Nat. Rev. Drug Discov.* 2012, 11, 125–140. [CrossRef]

21. Turczynski, S.; Titeux, M.; Pironon, N.; Hovnanian, A. Antisense-mediated exon skipping to reframe transcripts. In *Exon Skipping*; Springer: Clifton, NJ, USA, 2012; pp. 221–238.

22. Aartsma-Rus, A. Overview on DMD exon skipping. *Exon Skipp.* 2012, 867, 97–116.

23. Wilton, S.D.; Fall, A.M.; Harding, P.L.; McClurey, G.; Coleman, C.; Fletcher, S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. *Mol. Ther.* 2007, 15, 1288–1296. [CrossRef]

24. Syed, Y.Y. Eteplirsen: First global approval. *Drugs* 2016, 76, 1699–1704. [CrossRef] [PubMed]

25. Heo, Y.-A. Golodirsen: First Approval. *Drugs* 2020, 80, 329–333. [CrossRef]

26. Disterer, P.; Khoo, B. Antisense-mediated exon-skipping to induce gene knockdown. In *Exon Skipping*; Springer: Clifton, NJ, USA, 2012; pp. 289–305.

27. Du, L.; Gatti, R.A. Progress toward therapy with antisense-mediated splicing modulation. *Curr. Opin. Mol. Ther.* 2009, 11, 116–123.

28. Douglas, A.G.; Wood, M.J. Splicing therapy for neuromuscular disease. *Mol. Cell. Neurosci.* 2013, 56, 169–185. [CrossRef] [PubMed]

29. Prakash, V. Spinraza—A rare disease success story. *Gene Ther.* 2017, 24, 497.

30. El Marabti, E.; Younis, I. The cancer spliceome: Reprogramming of alternative splicing in cancer. *Front. Mol. Biosci.* 2018, 5, 80. [CrossRef]

31. Kurreck, J. Antisense technologies: Improvement through novel chemical modifications. *Eur. J. Biochem.* 2003, 270, 1628–1644. [CrossRef] [PubMed]

32. Wan, W.B.; Seth, P.P. The medicinal chemistry of therapeutic oligonucleotides. *J. Med. Chem.* 2016, 59, 9645–9667. [CrossRef] [PubMed]

33. Sierakowska, H.; Sambade, M.J.; Agrawal, S.; Kole, R. Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. *Proc. Natl. Acad. Sci. USA* 1996, 93, 12840–12844. [CrossRef]

34. Dunckley, M.G.; Manoharan, M.; Villet, P.; Eperon, I.C.; Dickson, G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. *Hum. Mol. Genet.* 1998, 7, 1083–1090. [CrossRef]

35. Lu, Q.L.; Mann, C.J.; Lou, F.; Bou-Gharios, G.; Morris, G.E.; Xue, S.-A.; Fletcher, S.; Partridge, T.A.; Wilton, S.D. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. *Nat. Med.* 2003, 9, 1009–1014. [CrossRef] [PubMed]
36. Lu, Q.L.; Rabinowitz, A.; Chen, Y.C.; Yokota, T.; Yin, H.; Alter, J.; Jadoon, A.; Bou-Gharios, G.; Partridge, T. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. *Proc. Natl. Acad. Sci. USA* 2008, 102, 198–203. [CrossRef] [PubMed]

37. Goemans, N.M.; Tulinius, M.; Van den Hauwe, M.; Kroksmark, A.-K.; Buyse, G.; Wilson, R.J.; van Deutekom, J.C.; de Kimpe, S.J.; Lourbakos, A.; Campion, G. Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: Results from an open-label extension study. *PloS ONE* 2016, 11, e0161955.

38. Relizani, K.; Griffith, G.; Echevarria, L.; Zarrouki, F.; Facchinetti, P.; Vaillend, C.; Leumann, C.; Garcia, L.; Goyenvalle, A. Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model. *Mol. Ther.-Nucleic Acids* 2017, 8, 144–157. [PubMed]

39. Goyenvalle, A.; Griffith, G.; Babbs, A.; El Andaloussi, S.; Ezzat, K.; Avril, A.; Dugovic, B.; Chaussenot, R.; Ferry, A.; Voit, T. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. *Nat. Med.* 2015, 21, 270–275. [PubMed]

40. Robin, V.; Griffith, G.; Carter, J.-P.L.; Leumann, C.J.; Garcia, L.; Goyenvalle, A. Efficient SMN rescue following subcutaneous Tricyclo-DNA antisense oligonucleotide treatment. *Mol. Ther.-Nucleic Acids* 2017, 7, 81–89. [CrossRef] [PubMed]

41. Renneberg, D.; Leumann, C.J. Watson–crick base-pairing properties of tricyclo-DNA. *J. Am. Chem. Soc.* 2002, 124, 5993–6002. [CrossRef] [PubMed]

42. Ittig, D.; Gerber, A.-B.; Leumann, C.J. Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes. *Nucleic Acids Res.* 2011, 39, 373–380. [CrossRef]

43. Aupy, P.; Echevarria, L.; Relizani, K.; Goyenvalle, A. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders. *Biomedicines* 2017, 6, 2. [CrossRef]

44. Koshkin, A.A.; Singh, S.K.; Nielsen, P.; Rajwanshi, V.K.; Kumar, R.; Meldgaard, M.; Olsen, C.E.; Wengel, J. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. *Tetrahedron* 1998, 54, 3607–3630.

45. Veedu, R.N.; Wengel, J. Locked nucleic acid as a novel class of therapeutic agents. *RNA Biol.* 2009, 6, 321–323. [CrossRef]

46. Aartsma-Rus, A.; Kaman, W.; Bremmer-Bout, M.; Janson, A.; Den Dunnen, J.; van Ommen, G.B.; Van Deutekom, J. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. *Gene Ther.* 2004, 11, 1391–1398. [CrossRef]

47. Egholm, M.; Buchardt, O.; Christensen, L.; Behrens, C.; Freier, S.M.; Driver, D.A.; Berg, R.H.; Kim, S.K.; Norden, B.; Nielsen, P.E. PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules. *Nature* 1993, 365, 566–568.

48. Yin, H.; Lu, Q.; Wood, M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. *Mol. Ther.* 2008, 16, 38–45. [CrossRef]

49. Yin, H.; Betts, C.; Saleh, A.F.; Ivanova, G.D.; Lee, H.; Seow, Y.; Kim, D.; Gait, M.J.; Wood, M.J. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. *Mol. Ther.* 2010, 18, 819–827. [CrossRef] [PubMed]

50. Schmajuk, G.; Sierakowska, H.; Kole, R. Antisense oligonucleotides with different backbones: Modification of splicing pathways and efficacy of uptake. *J. Biol. Chem.* 1999, 274, 21783–21789.

51. Fletcher, S.; Honeyman, K.; Fall, A.M.; Harding, P.L.; Johnsen, R.D.; Wilton, S.D. Dystrophin expression in the mdx mouse after localised and systematic administration of a morpholino antisense oligonucleotide. *J. Gene Med.* 2006, 8, 207–216. [CrossRef] [PubMed]

52. Heemskerk, H.A.; de Winter, C.L.; de Kimpe, S.J.; van Kuik-Romeijn, P.; Heuvelmans, N.; Platenburg, G.J.; van Ommen, G.J.B.; van Deutekom, J.C.; Aartsma-Rus, A. In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. *J. Gene Med.* 2009, 11, 257–266. [CrossRef]

53. Betts, C.; Saleh, A.F.; Arzumanov, A.A.; Hammond, S.M.; Godfrey, C.; Coursinadel, T.; Gait, M.J.; Wood, M.J. Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. *Mol. Ther.-Nucleic Acids* 2012, 1, e38. [CrossRef]

54. Young, C.S.; Pyle, A.D. exon Skipping Therapy. *Cell* 2016, 167, 1144. [CrossRef] [PubMed]

55. Le, B.T.; Agarwal, S.; Veedu, R.N. Evaluation of DNA segments in 2′-modified RNA sequences in designing efficient splice switching antisense oligonucleotides. *RSC Adv.* 2021, 11, 14029–14035. [CrossRef]

56. Le, B.T.; Hornum, M.; Sharma, P.K.; Nielsen, P.; Veedu, R.N. nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2′-deoxyuridine nucleotides induce exon-skipping in vitro. *RSC Adv.* 2017, 7, 54542–54545.

57. Le, B.T.; Chen, S.; Abramov, M.; Herdevijn, P.; Veedu, R.N. Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and d-altritol nucleic acid-modified 2′-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro. *Chem. Commun.* 2016, 52, 13467–13470. [CrossRef] [PubMed]

58. Le, B.T.; Adams, A.M.; Fletcher, S.; Wilton, S.D.; Veedu, R.N. Rational design of short locked nucleic acid-modified 2′-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. *Mol. Ther.-Nucleic Acids* 2017, 9, 155–161. [CrossRef] [PubMed]

59. Le, B.T.; Filichev, V.V.; Veedu, R.N. Investigation of twisted intercalating nucleic acid (TINA)-modified antisense oligonucleotides for splice modulation by induced exon-skipping in vitro. *RSC Adv.* 2016, 6, 95169–95172. [CrossRef] [PubMed]
60. Le, B.T.; Murayama, K.; Shabanpour, F.; Asanuma, H.; Veedu, R.N. Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes. *RSC Adv.* 2017, 7, 34049–34052. [CrossRef]

61. Chen, S.; Le, B.T.; Chakravartthi, M.; Kosbar, T.R.; Veedu, R.N. Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro. *Sci. Rep.* 2019, 9, 6078. [CrossRef]

62. Le, B.T.; Kosbar, T.R.; Veedu, R.N. Novel disulfide-bridged bioresponsive antisense oligonucleotide induces efficient splice modulation in muscle Myotubes in Vitro. *ACS Omega* 2020, 5, 18035–18039. [CrossRef]

63. Chen, S.; Le, B.T.; Rahimizadeh, K.; Shaikh, K.; Mohal, N.; Veedu, R.N. Synthesis of a morpholino nucleic acid (MNA)-uridine phosphoramidate, and exon skipping using MNA/2′-O-methyl mixmer antisense oligonucleotide. *Molecules* 2016, 21, 1582. [CrossRef]

64. Raguraman, P.; Wang, T.; Ma, L.; Jørgensen, P.T.; Wengel, J.; Veedu, R.N. Alpha-l-locked nucleic acid-modified antisense oligonucleotides induce efficient splice modulation in vitro. *Int. J. Mol. Sci.* 2020, 21, 2434. [CrossRef]

65. Jansen, B.; Zangemeister-Wittke, U. Antisense therapy for cancer—The time of truth. *Lancet Oncol.* 2002, 3, 672–683. [CrossRef]

66. National Cancer Institute. *What Is Cancer?* Available online: https://www.cancer.gov/about-cancer/understanding/what-is-cancer (accessed on 7 August 2019).

67. Zhu, S.; Mott, R.T.; Fry, E.A.; Taneya, P.; Kulik, G.; Sui, G.; Inoue, K. Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer. *Am. J. Pathol.* 2013, 183, 1339–1350. [PubMed]

68. Maglic, D.; Stovall, D.B.; Cline, J.M.; Fry, E.A.; Mallakin, A.; Taneya, P.; Caudell, D.L.; Willingham, M.C.; Sui, G.; Inoue, K. DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer. *J. Pathol.* 2015, 236, 90–102. [CrossRef] [PubMed]

69. Inoue, K.; Fry, E.A. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer. *Oncogene* 2007, 26, 1819–1827. [CrossRef] [PubMed]

70. Dean, N.M.; Bennett, C.F. Antisense oligonucleotide-based therapeutics for cancer. *Annu. Rev. Cancer. Biol.* 2003, 7, 167–185. [CrossRef] [PubMed]

71. Urbanski, L.M.; Leclair, N.; Anczukow, O. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. *Wiley Interdiscip. Rev. RNA* 2018, 9, e1476. [CrossRef]

72. Bonnal, S.C.; Lopez-Oreja, I.; Valcarcel, J. Roles and mechanisms of alternative splicing in cancer—Implications for care. *Nat. Rev. Clin. Oncol.* 2020, 17, 457–474. [CrossRef]

73. Escobar-Hoyos, L.; Knorr, K.; Abdel-Wahab, O. Aberrant RNA Splicing in Cancer. *Blood Cancer J.* 2013, 3, 234–236. [CrossRef]

74. Zhang, S.; Roeder, R.G. The Long and the Short of BRD4: Two Tales in Breast Cancer. *Mol. Cell* 2020, 78, 993–995. [CrossRef]

75. De Kouchkovsky, I.; Abdul-Hay, M. Acute myeloid leukemia: A comprehensive review and 2016 update. *Blood Cancer J.* 2016, 6, e441. [CrossRef]

76. David, C.J.; Manley, J.L. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. *Annu. Rev. Cancer. Biol.* 2010, 24, 2343–2364. [CrossRef]

77. Dias, N.; Stein, C. Antisense oligonucleotides: Basic concepts and mechanisms. *Mol. Cancer Ther.* 2002, 1, 347–355. [PubMed]

78. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987, 235, 177–182. [CrossRef] [PubMed]

79. Ziegler, R.G.; Hoover, R.N.; Pike, M.C.; Hildesheim, A.; Nomura, A.M.; West, D.W.; Wu-Williams, A.H.; Kolonel, L.N.; Horn-Ross, P.L.; Rosenthal, J.F. Migration patterns and breast cancer risk in Asian-American women. *Int. J. Cancer* 2000, 85, 1819–1827. [CrossRef] [PubMed]

80. Moasser, M.M. Targeting the function of the HER2 oncoprotein in human cancer therapeutics. *Oncogene* 2007, 26, 6577–6592. [CrossRef]

81. Wang, J.; Sazani, P.; Kole, R. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. *Int. J. Cancer* 2009, 124, 772–777. [CrossRef]

82. Pankratova, S.; Nielsen, B.N.; Shiraishi, T.; Nielsen, P.E. PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: Specific skipping of erbB-2 exon 13 for the ATP catalytic domain. *Int. J. Oncol.* 2010, 36, 29–38. [CrossRef]

83. Menard, S.; Casalini, P.; Campiglio, M.; Pupa, S.; Agresti, R.; Tagliabue, E. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. *Ann. Oncol.* 2001, 12, S15–S19. [CrossRef]

84. Dias, N.; Stein, C. Antisense oligonucleotides: Basic concepts and mechanisms. *Mol. Cancer Ther.* 2002, 1, 347–355. [PubMed]

85. Nielsen, T.O.; Sorensen, S.; Dagnaes-Hansen, F.; Kjems, L.; Sorensen, B. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. *Br. J. Cancer* 2013, 108, 2291–2298. [CrossRef] [PubMed]

86. De Kouchkovsky, I.; Abdul-Hay, M. Acute myeloid leukemia: A comprehensive review and 2016 update. *Blood Cancer J.* 2017, 7, e577. [CrossRef] [PubMed]
89. Lyu, X.; Xin, Y.; Mi, R.; Ding, J.; Wang, X.; Hu, J.; Fan, R.; Wei, X.; Song, Y.; Zhao, R.Y. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. *PloS ONE* **2014**, *9*, e92470.

90. Menssen, H.; Renkl, H.; Rodeck, U.; Maurer, J.; Notter, M.; Schwartz, S.; Reinhardt, R.; Thiel, E. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia* **1995**, *9*, 1060–1067.

91. Renshaw, J.; Orr, R.M.; Walton, M.I.; Te Poele, R.; Williams, R.D.; Wancewicz, E.V.; Monia, B.P.; Workman, P.; Pritchard-Jones, K. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. *Mol. Cancer Ther.* **2004**, *3*, 1467–1484.

92. Miwa, H.; Beran, M.; Saunders, G. Expression of the Wilms' tumor gene (WT1) in human leukemias. *Leukemia* **1992**, *6*, 405–409.

93. Bollum, F.J. Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. *Blood* **1979**, *54*, 1203–1215. [CrossRef]

94. Montazersaheb, S.; Kazemi, M.; Nabat, E.; Nielsen, P.E.; Hejazi, M.S. Downregulation of TdT expression through splicing modulation by antisense peptide nucleic acid (PNA). *Curr. Pharm. Biotechnol.* **2019**, *20*, 168–178. [PubMed]

95. Matthews, N.H.; Li, W.Q.; Qureshi, A.A.; Weinstock, M.A.; Cho, E. Epidemiology of Melanoma. In Cutaneous Melanoma: Etiology and Therapy; Ward, W.H., Farma, J.M., Eds.; Codon Publications, Brisbane, Australia, 2017.

96. Gembarska, A.; Luciani, F.; Fedele, C.; Russell, E.A.; Dewaele, M.; Villar, S.; Zwolinska, A.; Haupt, S.; de Lange, J.; Yip, D.; et al. MDM4 is a key therapeutic target in cutaneous melanoma. *Nat. Med.* **2012**, *18*, 1239–1247. [CrossRef] [PubMed]

97. Dewaele, M.; Tabaglio, T.; Willekens, K.; Bezzi, M.; Teo, S.X.; Low, D.H.; Koh, C.M.; Rambow, F.; Fiers, M.; Rogiers, A. Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. *J. Clin. Investig.* **2016**, *126*, 68–84. [CrossRef] [PubMed]

98. Chi, K.N.; Yu, E.Y.; Jacobs, C.; Bazov, J.; Kollmannsberger, C.; Higano, C.S.; Mukherjee, S.D.; Gleave, M.E.; Stewart, P.S.; Hotte, S.J. A phase I dose-escalation study of apatropesin (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. *Ann. Oncol.* **2016**, *27*, 1116–1122. [CrossRef]

99. Bellmunt, J.; Eigl, B.J.; Senkus-Konefka, E.; Loriot, Y.; Twardowski, P.; Castellano, D.E.; Blais, N.; Sridhar, S.S.; Sternberg, C.N.; Retz, M.; et al. First-line randomized phase II study of gemcitabine/cisplatin plus apatropesin or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. *J. Clin. Oncol.* **2015**, *33*, 4503. [CrossRef]

100. Choueiri, T.K.; Hahn, N.M.; Werner, L.; Regan, M.M.; Rosenberg, J.E. Borealis-2: A randomized phase II study of OGX-427 (apatropesin) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Council GU12-160). *J. Clin. Oncol.* **2017**, *35*, 289. [CrossRef]

101. Ko, A.H.; Murphy, P.B.; Peyton, J.D.; Shiple, D.L.; Al-Hazzouri, A.; Rodrigue, F.A.; Womack, M.S.T.; Xiaodong, H.Q.; Waterhouse, D.M.; Tempero, M.A.; et al. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatropesin or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. *Oncologist* **2017**, *22*, 1427–e129. [CrossRef]

102. Schmid, P.; Blackhall, F.; Muthukumar, D.; Lester, J.; Khan, S.; Adams, J.; Illsley, M.; Macgregor, C.; Owadally, W.; Sarker, S.J.; et al. A Phase II randomisation, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatropesin (OGX-427) in advanced squamous cell lung cancers. *Ann. Oncol.* **2017**, *28*. [CrossRef]

103. Yu, E.Y.; Ellard, S.L.; Hotte, S.J.; Gingerich, J.R.; Joshua, A.M.; Gleave, M.E.; Chi, K.N. A randomized phase 2 study of a HSP27 targeting antisense, apatropesin with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. *Investig. New Drugs* **2018**, *36*, 278–287. [CrossRef]

104. Spigel, D.R.; Shiple, D.L.; Waterhouse, D.M.; Jones, S.F.; Ward, P.J.; Shih, K.C.; Hemphill, B.; McLeod, M.; Whorf, R.C.; Page, R.D.; et al. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatropesin (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. *Oncologist* **2019**, *24*, e1409–e1416. [CrossRef]

105. Ross, S.J.; Revenko, A.S.; Hanson, L.L.; Elliston, R.; Stanisewszka, A.; Whalley, N.; Pandey, S.K.; Revill, M.; Rooney, C.; Buckett, L.K.; et al. Targeting KRAS-dependent tumors with apatropesin, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. *Sci. Transl. Med.* **2017**, *9*, eaal5253. [CrossRef] [PubMed]

106. Phase I Dose-Escalation Study of AZD4785 in Patients with Advanced Solid Tumours. Available online: https://astrazenecagrouptrials.pharmc.com/ST/Submission/View?id=24623 (accessed on 7 October 2021).

107. Chowdhury, S.; Burris, H.A.; Patel, M.; Infante, J.R.; Jones, S.F.; Voskoboynik, M.; Parry, K.; Elvin, P.; Coleman, T.; Gardiner, H.; et al. A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2 antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. *J. Clin. Investig.* **2016**, *126*, 68–84. [CrossRef] [PubMed]

108. Dewaele, M.; Tabaglio, T.; Willekens, K.; Bezzi, M.; Teo, S.X.; Low, D.H.; Koh, C.M.; Rambow, F.; Fiers, M.; Rogiers, A. Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. *J. Clin. Investig.* **2016**, *126*, 68–84. [CrossRef] [PubMed]

109. Dhuri, K.; Bechtold, C.; Quijano, E.; Pham, H.; Gupta, A.; Vikram, A.; Bahal, R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. *J. Clin. Med.* **2020**, *9*, 2004. [CrossRef] [PubMed]

110. Dong, D.S.; Younes, A.; Fayad, L.; Fowler, N.H.; Hagemeister, F.B.; Mistry, R.; Nemunaitis, J.J.; Borad, M.J.; Bryce, A.H.; Yamashita, M.; et al. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. *J. Clin. Oncol.* **2013**, *31*, 8523. [CrossRef]

111. Reilley, M.J.; McCoon, P.; Cook, C.; Lyne, P.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial. *J. Immunother. Cancer* **2018**, *6*, 119. [CrossRef] [PubMed]

112. Ribrag, V.; Lee, S.T.; Rizzieri, D.; Dyer, M.J.S.; Fayad, L.; Kurzrock, R.; Andritsos, L.; Bouabdallah, R.; Hayat, A.; Bacon, L.; et al. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen.
in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clin. Lymphoma Myeloma Leuk.* **2021**, *21*, 309–317. [CrossRef] [PubMed]

113. Ohanian, M.; Ashizawa, A.T.; Garcia-Manero, G.; Pennmaraju, N.; Kadia, T.; Jabbour, E.; Ravandi, F.; Borthakur, G.; Andreeff, M.; Konopleva, M.; et al. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: A single-centre, open-label, dose-escalation, phase 1/1b trial. *Lancet Haematol.* **2018**, *5*, e136–e146. [CrossRef]

114. Tantravahi, R.V.; Reddy, E.P. myb. In *Encyclopedia of Cancer*, 2nd ed.; Bertino, J.R., Ed.; Academic Press: New York, NY, USA, 2002; pp. 287–296. [CrossRef]

115. C-myb Antisense Oligonucleotide G4460. Available online: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ncit.encode=C154](https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ncit.encode=C154) (accessed on 19 October 2021).

116. Luger, S.M.; O’Brien, S.G.; Ratajczak, J.; Ratajczak, M.Z.; Mick, R.; Stadtmueller, E.A.; Nowell, P.C.; Goldman, J.M.; Gewirtz, A.M. Oligodeoxynucleotide-mediated inhibition of myb gene expression in autografted bone marrow: A pilot study. *Blood* **2002**, *99*, 1150–1158. [CrossRef]

117. Greenberger, L.M.; Horak, I.D.; Filpula, D.; Sapra, P.; Westergaard, M.; Frydenlund, H.F.; Albaek, C.; Schroder, H.; Orum, H. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. *Mol. Cancer Ther.* **2008**, *7*, 3598–3608. [CrossRef]

118. Patnaik, A.; Chiorean, E.G.; Tolcher, A.; Papadopoulos, K.; Beeram, M.; Kee, D.; Waddell, M.; Gilles, E.; Buchbinder, A. A novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. *J. Clin. Oncol.* **2009**, *27*, 2564. [CrossRef]

119. Jeong, W.; Rapisarda, A.; Park, S.R.; Kinders, R.J.; Chen, A.; Melillo, G.; Turkbey, B.; Steinberg, S.M.; Choyke, P.; Doroshow, J.H.; et al. Pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. *Cancer Chemother. Pharmacol.* **2014**, *73*, 343–348. [CrossRef] [PubMed]

120. Wu, J.; Contratto, M.; Shanbhogue, K.P.; Manji, G.A.; O’Neil, B.H.; Noonan, A.; Tudor, R.; Lee, R. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1alpha in advanced hepatocellular carcinoma. *World J. Clin. Oncol.* **2019**, *10*, 149–160. [CrossRef] [PubMed]

121. Morris, M.J.; Cordon-Cardo, C.; Kelly, W.K.; Slovin, S.F.; Siedlecki, K.; Regan, K.P.; DiPola, R.; Ratajczak, M.Z.; Mick, R.; Stadtmauer, E.A.; Nowell, P.C.; Goldman, J.M.; Gewirtz, A.M. alpha RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. *Mol. Cancer Ther.* **2008**, *7*, 3598–3608. [CrossRef]

122. Marcucci, G.; Byrd, J.C.; Dai, G.; Klisovic, M.I.; Kourlas, P.J.; Young, D.C.; Cataland, S.R.; Fisher, D.B.; Lucas, D.; Chan, K.K.; et al. Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. *Blood* **2003**, *101*, 425–432. [CrossRef]

123. Rudin, C.M.; Otterson, G.A.; Mauer, A.M.; Villalona-Calero, M.A.; Tomek, R.; Prange, B.; George, C.M.; Szeto, L.; Vokes, E.E. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. *Ann. Oncol.* **2002**, *13*, 539–545. [CrossRef]

124. Mita, M.M.; Ochoa, L.; Rowinsky, E.K.; Kuhn, J.; Schwartz, G.; Hammond, L.A.; Patnaik, A.; Yeh, I.T.; Izbicka, E.; Berg, K.; et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and taxane chemotherapy in patients with advanced cancer. *Appl. Immunohistochem. Mol. Morphol.* **2005**, *13*, 6–13. [CrossRef] [PubMed]

125. Maruccci, G.; Byrd, J.C.; Dai, G.; Klisovic, M.I.; Kourlas, P.J.; Young, D.C.; Cataland, S.R.; Fisher, D.B.; Lucas, D.; Chan, K.K.; et al. Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. *Blood* **2003**, *101*, 425–432. [CrossRef] [PubMed]

126. Wu, J.; Contratto, M.; Shanbhogue, K.P.; Manji, G.A.; O’Neil, B.H.; Noonan, A.; Tudor, R.; Lee, R. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1alpha in advanced hepatocellular carcinoma. *World J. Clin. Oncol.* **2019**, *10*, 149–160. [CrossRef] [PubMed]

127. Morris, M.J.; Cordon-Cardo, C.; Kelly, W.K.; Slovin, S.F.; Siedlecki, K.; Regan, K.P.; DiPola, R.; Ratajczak, M.Z.; Mick, R.; Stadtmauer, E.A.; Nowell, P.C.; Goldman, J.M.; Gewirtz, A.M. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. *Appl. Immunohistochem. Mol. Morphol.* **2005**, *13*, 6–13. [CrossRef] [PubMed]

128. Maruccci, G.; Byrd, J.C.; Dai, G.; Klisovic, M.I.; Kourlas, P.J.; Young, D.C.; Cataland, S.R.; Fisher, D.B.; Lucas, D.; Chan, K.K.; et al. Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. *Blood* **2003**, *101*, 425–432. [CrossRef] [PubMed]

129. Moore, J.; Seiter, K.; Kolitz, J.; Stock, W.; Giles, E.; Kalaycio, M.; Zenk, D.; Marucci, G. A Phase II study of Bcl-2 antisense oligomer (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. *Leuk. Res.* **2006**, *30*, 777–783. [CrossRef]

130. Agarwala, S.S.; Keilholz, U.; Gilles, E.; Bedikian, A.Y.; Wu, J.; Kay, R.; Stein, C.A.; Itri, L.M.; Suciu, S.; Eggermont, A.M. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). *Eur. J. Cancer* **2009**, *45*, 1807–1814. [CrossRef]

131. Chanan-Khan, A.A.; Niesvizky, R.; Kohlschmidt, J.; Mrozek, K.; Carroll, A.J.; Eisfeld, A.K.; Wang, E.S.; et al. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). *Blood Adv.* **2021**, *5*, 2775–2787. [CrossRef] [PubMed]
132. Bedikian, A.Y.; Garbe, C.; Conry, R.; Lebbe, C.; Grob, J.J.; Genasense Melanoma Study G. Decarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: ‘The AGENDA trial’. *Melanoma Res.* 2014, 24, 237–243. [CrossRef] [PubMed]

133. Desai, A.A.; Schilsky, R.L.; Young, A.; Janisch, L.; Stadler, W.M.; Vogelzang, N.J.; Cadden, S.; Wright, J.A.; Ratain, M.J. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. *Ann. Oncol.* 2005, 16, 958–965. [CrossRef] [PubMed]

134. Stadler, W.M.; Desai, A.A.; Quinn, D.I.; Bukowski, R.; Poiesz, B.; Kardinal, C.G.; Lewis, N.; Makalinao, A.; Murray, P.; Torti, F.M. A Phase I/II study of GTI-2040 and capcitabine in patients with renal cell carcinoma. *Cancer Chemother. Pharmacol.* 2008, 61, 689–694. [CrossRef]

135. Juhasza, A.; Vassilakos, A.; Chew, H.K.; Gandara, D.; Yen, Y. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. *Oncol. Rep.* 2006, 15, 1299–1304. [CrossRef]

136. Klisovic, R.B.; Blum, W.; Wei, X.; Liu, S.; Liu, Z.; Xie, Z.; Vukosavljevic, T.; Kefauver, C.; Huynh, L.; Pang, J.; et al. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. *Clin. Cancer Res.* 2008, 14, 3889–3895. [CrossRef]

137.leigh, N.B.; Laurie, S.A.; Chen, X.E.; Ellis, P.; Shepherd, F.A.; Knox, J.J.; Goss, G.; Burkes, R.L.; Pond, G.R.; Dick, C.; et al. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: A study of the PMH phase II consortium. *J. Thorac. Oncol.* 2009, 4, 1163–1169. [CrossRef]

138. Shibata, S.I.; Doroshow, J.H.; Frankel, P.; Synold, T.W.; Yen, Y.; Gandara, D.R.; Lenz, H.J.; Chow, W.A.; Leong, L.A.; Lim, D.; et al. Phase I trial of GTI-2040, oxaliplatin, and capcitabine in advanced metastatic solid tumors: A California Cancer Consortium Study. *Cancer Chemother. Pharmacol.* 2006, 64, 1149–1155. [CrossRef]

139. Sridhar, S.S.; Canil, C.M.; Chi, K.N.; Hotte, S.J.; Ernst, S.; Wang, L.; Chen, E.X.; Juhasza, A.; Yen, Y.; Murray, P.; et al. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. *Cancer Chemother. Pharmacol.* 2011, 67, 927–933. [CrossRef] [PubMed]

140. Mannargudi, M.B.; Deb, S. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: Is it a viable cancer therapy? *J. Cancer Res. Clin. Oncol.* 2017, 143, 1499–1529. [CrossRef]

141. Nemunaitis, J.; Holmlund, J.T.; Kraynak, M.; Richards, D.; Bruce, J.; Ognoskie, N.; Kwoh, T.J.; Geary, R.; Dorr, A.; Von Hoff, D.; et al. Phase I/II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC clinical trials group study (NCIC IND.116). *Clin. Cancer Res.* 2000, 6, 1626–1631. [PubMed]

142. Oza, A.M.; Eliot, L.; Swenerton, K.; Faught, W.; Ghatee, P.; Carey, M.; McIntosh, L.; Dorr, A.; Holmlund, J.T.; Eisenhauer, E. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC clinical trials group study (NCIC IND.116)®. *Gynecol. Oncol.* 2003, 89, 129–133. [CrossRef]

143. Cripps, M.C.; Figueredo, A.T.; Oza, A.M.; Taylor, M.J.; Fields, A.L.; Holmlund, J.T.; Leong, L.A.; Geary, R.S.; Eisenhauer, E.A. Phase II randomized study of ISIS 5321 and ISIS 5312 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada clinical trials group study. *Clin. Cancer Res.* 2002, 8, 2188–2192.

144. Oza, A.M.; Eliot, L.; Swenerton, K.; Faught, W.; Ghatee, P.; Carey, M.; McIntosh, L.; Dorr, A.; Holmlund, J.T.; Eisenhauer, E. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC clinical trials group study (NCIC IND.116)®. *Gynecol. Oncol.* 2003, 89, 129–133. [CrossRef]

145. Cripps, M.C.; Figueredo, A.T.; Oza, A.M.; Taylor, M.J.; Fields, A.L.; Holmlund, J.T.; Leong, L.A.; Geary, R.S.; Eisenhauer, E.A. Phase II randomized study of ISIS 5321 and ISIS 5312 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada clinical trials group study. *Clin. Cancer Res.* 2002, 8, 2188–2192.

146. Rudin, C.M.; Marshall, J.L.; Huang, C.H.; Kindler, H.L.; Zhang, C.; Kumar, D.; Gokhale, P.C.; Steinberg, J.; Wasnaki, S.; Kasid, U.N.; et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: A phase I study. *Clin. Cancer Res.* 2004, 10, 7242–7251. [CrossRef]

147. Dritschilo, A.; Huang, C.H.; Rudin, C.M.; Marshall, J.; Collins, B.; Dul, J.L.; Zhang, C.; Kumar, D.; Gokhale, P.C.; Ahmad, A.; et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. *Clin. Cancer Res.* 2006, 12, 1251–1259. [CrossRef]

148. Chi, K.N.; Eisenhauer, E.; Fazioli, L.; Jones, E.C.; Goldenberg, S.L.; Powers, J.; Tu, D.; Gleave, M.E. A phase I pharmacokinetic and pharmacodynamic study of OXG-011, a 2’-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. *J. Natl. Cancer Inst.* 2005, 97, 1287–1296. [CrossRef]

149. Chi, K.N.; Siu, L.L.; Hirst, H.; Hotte, S.; Knox, J.; Kollmansberger, C.; Gleave, M.; Guns, E.; Powers, J.; Walsh, W.; et al. A phase I study of OXG-011, a 2′-methoxyethyl phosphorothioate oligonucleotide, in combination with docetaxel in patients with advanced cancer. *Clin. Cancer Res.* 2008, 14, 833–839. [CrossRef]

150. Chia, S.; Dent, S.; Ellard, S.; Ellis, P.M.; Vandenberg, T.; Gelmon, K.; Powers, J.; Walsh, W.; Seymour, L.; Eisenhauer, E.A. Phase II trial of OXG-011 in combination with docetaxel in metastatic breast cancer. *Clin. Cancer Res.* 2009, 15, 708–713. [CrossRef]

151. Chi, K.N.; Hotte, S.J.; Yu, E.Y.; Tu, D.; EiGL, B.J.; Tannock, I.; Saad, F.; North, S.; Powers, J.; Gleave, M.E.; et al. Randomized phase II study of docetaxel and prednisone with or without OXG-011 in patients with metastatic castration-resistant prostate cancer. *J. Clin. Oncol.* 2010, 28, 4247–4254. [CrossRef] [PubMed]
| Page | Authors | Title |
|------|---------|-------|
| 161 | Sridharan, K.; Gogtay, N.J. | Therapeutic nucleic acids: Current clinical status. |
| 162 | Knox, J.J.; Chen, X.E.; Feld, R.; Nematollahi, M.; Cheiken, R.; Pond, G.; Zwiebel, J.A.; Gill, S.; Moore, M. | A phase I-II study of docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. J. Clin. Oncol. 2009, 20, 1264–1269. [CrossRef] [PubMed] |
| 163 | Marcucci, G.; Stock, W.; Dai, G.; Klsivic, R.B.; Liu, S.; Klisovic, M.I.; Blum, W.; Kefauver, C.; Sher, D.A.; Green, M.; et al. | Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 2005, 23, 3404–3411. [CrossRef] |
| 164 | Mays, T.A.; Mita, A.C.; Takimoto, C.; Petro, D.; Egorin, M.J.; Patnaik, A.; Papadopoulos, K.; Rowinsky, E.; Goldstone, M.; Tolcher, A. | Bcl-2 biomodulation with oblimersen sodium in combination with FOLFOX4 chemotherapy: A phase I study in metastatic colon carcinoma. J. Clin. Oncol. 2005, 23, 3158. [CrossRef] |
| 165 | Pro, B.; Leber, B.; Smith, M.; Fayad, L.; Romaguera, J.; Hagemeister, F.; Rodriguez, A.; McLaughlin, P.; Samaniego, F.; Zwiebel, J.; et al. | Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br. J. Haematol. 2008, 143, 355–360. [CrossRef] [PubMed] |
| 166 | Xuvarna, V.; Singh, V.; Murahari, M. | Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. Eur. J. Pharmacol. 2019, 862, 172655. [CrossRef] |
| 167 | Bediakian, A.Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, U.; Pavlick, A.C.; DeConti, R.; Hersh, E.M.; Hersey, P.; et al. | Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J. Clin. Oncol. 2006, 24, 4738–4745. [CrossRef] [PubMed] |
| 168 | Tentori, L.; Lalchand, A.; Easterday, P.L.; Graziani, G. | Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol. Sci. 2013, 34, 656–666. [CrossRef] |
174. Badros, A.Z.; Goloubeva, O.; Rapoport, A.P.; Ratterree, B.; Gahres, N.; Meisenberg, B.; Takebe, N.; Heyman, M.; Zwiebel, J.; Streicher, H.; et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. *J. Clin. Oncol.* 2005, 23, 4089–4099. [CrossRef]

175. Klisovic, R.B.; Blum, W.; Liu, Z.; Xie, Z.; Kefauver, C.; Huynh, L.; Zwiebel, J.A.; Devine, S.M.; Byrd, J.C.; Grever, M.R.; et al. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. *Leuk. Lymphoma* 2014, 55, 1332–1336. [CrossRef] [PubMed]

176. Kirschbaum, M.H.; Frankel, P.; Synold, T.W.; Xie, Z.; Yen, Y.; Popplewell, L.; Chen, R.; Aljitiawi, O.; Tuscano, J.M.; Chan, K.K.; et al. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase, in acute leukemias: A California Cancer Consortium study. *Leuk. Lymphoma* 2007, 57, 2307–2314. [CrossRef]

177. Malik, L.; Zwiebel, A.; Cooper, J. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors. *Cancer Chemother. Pharmacol.* 2018, 82, 533–539. [CrossRef] [PubMed]

178. Ritch, P.; Rudin, C.M.; Bitran, J.D.; Edelman, M.J.; Makalinao, A.; Irwin, D.; Lilenbaum, R.; Petersen, P.; John, W.J. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer* 2006, 52, 173–180. [CrossRef]

179. Gradishar, W.; O’Neill, A.; Cobleigh, M.; Goldstein, L.; Davidson, N. A phase II trial with antisense oligonucleotide ISIS 3521/Cgp 64128a in patients (pts) with metastatic breast cancer (MBC): ECOG Trial 3197. In Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, USA, 12–15 May 2001.

180. Steinberg, J.L.; Mendelson, D.S.; Block, H.; Green, S.B.; Shu, V.S.; Parker, K.; Cullinan, P.; Dul, J.L.; von Hoff, D.D.; Gordon, M.S. Phase I study of LRenaAON-ETU, an easy-to-use formulation of liposome entrapped c-raf antisense oligonucleotide, in advanced cancer patients. *J. Clin. Oncol.* 2005, 23, 3214. [CrossRef]

181. Xu, P.; Dong, X.F.; Li, X.P.; Li, J. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. *World J. Gastroenterol.* 2015, 21, 8262–8270. [CrossRef]

182. Laskin, J.J.; Nicholas, G.; Lee, C.; Gitlitz, B.; Vincent, M.; Cormier, Y.; Stephenson, J.; Ung, Y.; Sanborn, R.; Pressnail, B.; et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. *J. Thorac. Oncol.* 2012, 7, 579–586. [CrossRef]

183. Blumenstein, B.; Saad, F.; Hotte, S.; Chi, K.N.; Eigl, B.; Gleave, M.; Jacobs, C. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. *Cancer Med.* 2013, 2, 468–477. [CrossRef]

184. de Liano, A.G.; Reig, O.; Mellado, B.; Martin, C.; Rull, E.U.; Aljitiawi, O.; Tuscano, J.M.; Chan, K.K.; et al. Phase II study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase, in acute leukemias: A California Cancer Consortium study. *Leuk. Lymphoma* 2007, 57, 2307–2314. [CrossRef] [PubMed]

185. Gagliardi, M.; Ashizawa, A.T. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. *Biomedicines* 2021, 9, 433. [CrossRef] [PubMed]

186. Hunter, M.A.; Currie, M.J.; Robinson, B.A.; Dachs, G.U. Optimizing transfection of primary human umbilical vein endothelial cells using commercially available chemical transfection reagents. *J. Biomat. Tech. JBT* 2010, 21, 66–72. [PubMed]

187. Akhtar, S.; Hughes, M.D.; Khan, A.; Bibby, M.; Hussain, M.; Nawaz, Q.; Double, J.; Sayyed, P. The delivery of antisense therapeutics. *Adv. Drug Deliv. Rev.* 2000, 44, 3–21. [CrossRef]

188. Bielinska, A.; Kukowska-Latallo, J.F.; Johnson, J.; Tomalia, D.A.; Baker, J.R., Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. *Nucleic Acids Res.* 1996, 24, 2176–2182. [CrossRef] [PubMed]

189. Wu, G.Y.; Wu, C.H. Receptor-mediated gene delivery and expression in vivo. *J. Biol. Chem.* 1988, 263, 14621–14624. [CrossRef]
198. Lewis, K.J.; Irwin, W.J.; Akhtar, S. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: Characterization of P (LA-GA) copolymer microspheres in vitro. J. Drug Target. 1998, 5, 291–302. [CrossRef]

199. Putney, S.D.; Brown, J.; Cucco, C.; Lee, R.; Skorski, T.; Leonetti, C.; Geiser, T.; Calabretta, B.; Zupi, G.; Zon, G. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense Nucleic Acid Drug Dev. 1999, 9, 451–458. [CrossRef] [PubMed]

200. Khan, A.; Sommer, W.; Fuxe, K.; Akhtar, S. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. J. Drug Target. 2000, 8, 319–334. [CrossRef]

201. Kher, G.; Trehan, S.; Misra, A. Antisense oligonucleotides and RNA interference. Chull. Delit. Ther. Genom. Proteom. 2011, 325–386.

202. Dong, L.; Xia, S.; Chen, H.; Chen, J.; Zhang, J. Spleen-specific suppression of TNF-α by cationic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal models. Biomaterials 2009, 30, 4416–4426. [CrossRef]

203. Lou, X.; Garrett, K.L.; Rakoczy, P.E.; Chirila, T.V. Synthetic hydrogels as carriers in antisense therapy: Preliminary evaluation of an oligodeoxynucleotide covalent conjugate with a copolymer of 1-vinyl-2-pyrrolidinone and 2-hydroxyethyl methacrylate. J. Biomater. Appl. 2001, 15, 307–320. [CrossRef]

204. Javadzadeh, Y.; Bahari, L.A. Therapeutic nanostructures for dermal and transdermal drug delivery. In Nano and Microscale Drug Delivery Systems; Elsevier: Amsterdam, The Netherlands, 2017; pp. 131–146.

205. Prochiantz, A. Messenger proteins: Homeoproteins, TAT and others. Curr. Opin. Cell Biol. 2000, 12, 400–406. [CrossRef]

206. McClorey, G.; Banerjee, S. Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics. Curr. Opin. Cell Biol. 2018, 6, 51. [CrossRef]

207. Pichon, C.; Freulon, I.; Midoux, P.; Mayer, R.; Monsigny, M.; Roche, A.-C. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Dev. 1997, 7, 335–343. [CrossRef] [PubMed]

208. Bolhassani, A.; Jafarzade, B.S.; Mardani, G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides 2017, 87, 50–63. [CrossRef] [PubMed]

209. Novak, J.S.; Jaiswal, J.K.; Partridge, T.A. The macrophage as a Trojan horse for antisense oligonucleotide delivery. Expert Opin. Ther. Targets 2018, 22, 463–466. [PubMed]

210. Sun, D.; Zhuang, X.; Zhang, S.; Deng, Z.-B.; Grizzle, W.; Miller, D.; Zhang, H.-G. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv. Drug Deliv. Rev. 2013, 65, 342–347. [CrossRef]

211. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654–659. [CrossRef]

212. Peinado, H.; Aleckovic, M.; Lavotshkin, S.; Matei, I.; Costa-Silva, B.; Moreno-Bueno, G.; Hergueta-Redondo, M.; Williams, C.; Garcia-Santos, G.; Ghajar, C.M. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MEK. Nat. Med. 2012, 18, 883–891.

213. Liu, R.; Liu, J.; Ji, X.; Liu, Y. Synthetic nucleic acids delivered by exosomes: A potential therapeutic for generelated metabolic brain diseases. Metab. Brain Dis. 2013, 28, 551–562.

214. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341–345. [CrossRef]

215. Jeong, K.; Jeong, S.; Kim, J.A.; Rhee, W.J. Exosome-based antisense locked nucleic acid delivery for inhibition of type II collagen degradation in chondrocyte. J. Ind. Eng. Chem. 2019, 74, 126–135. [CrossRef]

216. Zewert, T.E.; Pliquet, U.F.; Langer, R.; Weaver, J.C. Transdermal transport of DNA antisense oligonucleotides by iontophoresis and electroporation. Biochem. Biophys. Res. Commun. 1995, 212, 286–292. [CrossRef]

217. Regnier, V.; Prétat, V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res. 1998, 15, 1596–1602. [CrossRef] [PubMed]

218. Bergan, R.; Connell, Y.; Fahmy, B.; Neckers, L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 1993, 21, 3567–3573. [CrossRef]

219. Regnier, V.; De Morre, N.; Jadoul, A.; Prétat, V. Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int. J. Pharm. 1999, 184, 147–156. [CrossRef]

220. Zavaglia, D.; Normand, N.; Brewis, N.; O’hare, P.; Favrot, M.-C.; Coll, J.-L. VP22-mediated and light-activated delivery of an anti-c-rafi antisense oligonucleotide improves its activity after intratumoral injection in nude mice. Mol. Ther. 2003, 8, 840–845. [PubMed]

221. Brewis, N.; Phelan, A.; Normand, N.; Choolun, E.; O’hare, P. Particle assembly incorporating a VP22–BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis. Mol. Ther. 2003, 7, 262–270. [CrossRef]

222. Normand, N.; Valamanesh, F.; Savoldelli, M.; Mascarelli, F.; Ben Ezra, D.; Courtois, Y.; Behar-Cohen, F. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol. Vis. 2005, 11, 184–191.

223. Kontturi, L.-S.; Van Den Dikkenberg, J.; Urtti, A.; Hennink, W.E.; Mastrobbattista, E. Light-triggered cellular delivery of oligonucleotides. Pharmaceutics 2019, 11, 90. [CrossRef] [PubMed]

224. Haag, P.; Frauscher, F.; Gradl, J.; Seitz, A.; Schäfer, G.; Lindner, J.R.; Klibanov, A.L.; Bartsch, G.; Klocker, H.; Eder, I.E. Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J. Steroid Biochem. Mol. Biol. 2006, 102, 103–113. [CrossRef] [PubMed]
225. Unger, E.C.; Hersh, E.; Vannan, M.; McCreery, T. Gene delivery using ultrasound contrast agents. *Echocardiography* 2001, 18, 355–361. [CrossRef] [PubMed]

226. Negishi, Y.; Ishii, Y.; Nirasawa, K.; Sasaki, E.; Endo-Takahashi, Y.; Suzuki, R.; Maruyama, K. PMO delivery system using bubble liposomes and ultrasound exposure for duchenne muscular dystrophy treatment. In *Duchenne Muscular Dystrophy*; Springer: Clifton, NJ, USA, 2018; pp. 185–192.